<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Med</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Med</journal-id><journal-id journal-id-type="pmc-domain-id">2745</journal-id><journal-id journal-id-type="pmc-domain">jclinmed</journal-id><journal-id journal-id-type="publisher-id">jcm</journal-id><journal-title-group><journal-title>Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2077-0383</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10059265</article-id><article-id pub-id-type="pmcid-ver">PMC10059265.1</article-id><article-id pub-id-type="pmcaid">10059265</article-id><article-id pub-id-type="pmcaiid">10059265</article-id><article-id pub-id-type="pmid">36983294</article-id><article-id pub-id-type="doi">10.3390/jcm12062294</article-id><article-id pub-id-type="publisher-id">jcm-12-02294</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Maule</surname><given-names initials="M">Matteo</given-names></name><xref rid="af1-jcm-12-02294" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1690-6774</contrib-id><name name-style="western"><surname>Olivieri</surname><given-names initials="B">Bianca</given-names></name><xref rid="af1-jcm-12-02294" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guarnieri</surname><given-names initials="G">Gabriella</given-names></name><xref rid="af2-jcm-12-02294" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7093-777X</contrib-id><name name-style="western"><surname>De Franceschi</surname><given-names initials="L">Lucia</given-names></name><xref rid="af3-jcm-12-02294" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6465-5119</contrib-id><name name-style="western"><surname>Martinelli</surname><given-names initials="N">Nicola</given-names></name><xref rid="af3-jcm-12-02294" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vaia</surname><given-names initials="R">Rachele</given-names></name><xref rid="af1-jcm-12-02294" ref-type="aff">1</xref><xref rid="af3-jcm-12-02294" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4747-4655</contrib-id><name name-style="western"><surname>Argentino</surname><given-names initials="G">Giuseppe</given-names></name><xref rid="af3-jcm-12-02294" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vianello</surname><given-names initials="A">Andrea</given-names></name><xref rid="af2-jcm-12-02294" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4172-3216</contrib-id><name name-style="western"><surname>Senna</surname><given-names initials="G">Gianenrico</given-names></name><xref rid="af1-jcm-12-02294" ref-type="aff">1</xref><xref rid="af3-jcm-12-02294" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7383-1487</contrib-id><name name-style="western"><surname>Caminati</surname><given-names initials="M">Marco</given-names></name><xref rid="af3-jcm-12-02294" ref-type="aff">3</xref><xref rid="c1-jcm-12-02294" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Calzetta</surname><given-names initials="L">Luigino</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-jcm-12-02294"><label>1</label>Allergy Unit and Asthma Center, Verona University Hospital, 37134 Verona, Italy</aff><aff id="af2-jcm-12-02294"><label>2</label>Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35128 Padua, Italy</aff><aff id="af3-jcm-12-02294"><label>3</label>Department of Medicine, University of Verona, 35134 Verona, Italy</aff><author-notes><corresp id="c1-jcm-12-02294"><label>*</label>Correspondence: <email>marco.caminati@univr.it</email></corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2023</year></pub-date><volume>12</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">431426</issue-id><elocation-id>2294</elocation-id><history><date date-type="received"><day>10</day><month>2</month><year>2023</year></date><date date-type="rev-recd"><day>05</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>13</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>30</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-03-30 18:10:11.880"><day>30</day><month>03</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jcm-12-02294.pdf"/><abstract><p>Bronchial asthma is the most frequent inflammatory non-communicable condition affecting the airways worldwide. It is commonly associated with concomitant conditions, which substantially contribute to its burden, whether they involve the lung or other districts. The present review aims at providing an overview of the recent acquisitions in terms of asthma concomitant systemic conditions, besides the commonly known respiratory comorbidities. The most recent research has highlighted a number of pathobiological interactions between asthma and other organs in the view of a shared immunological background underling different diseases. A bi-univocal relationship between asthma and common conditions, including cardiovascular, metabolic or neurodegenerative diseases, as well as rare disorders such as sickle cell disease, &#945;1-Antitrypsin deficiency and immunologic conditions with hyper-eosinophilia, should be considered and explored, in terms of diagnostic work-up and long-term assessment of asthma patients. The relevance of that acquisition is of utmost importance in the management of asthma patients and paves the way to a new approach in the light of a personalized medicine perspective, besides targeted therapies.</p></abstract><kwd-group><kwd>asthma</kwd><kwd>eosinophils</kwd><kwd>wheezing</kwd><kwd>&#945;1-Antitrypsin deficiency</kwd><kwd>immunodeficiencies</kwd><kwd>sickle cell disease</kwd><kwd>cognitive impairment</kwd><kwd>obesity</kwd><kwd>cardiovascular risk</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-jcm-12-02294"><title>1. Introduction</title><p>Bronchial asthma is the most frequent inflammatory non-communicable condition affecting the airways worldwide [<xref rid="B1-jcm-12-02294" ref-type="bibr">1</xref>]. It is commonly associated with concomitant conditions, which substantially contribute to its burden, whether they involve the lung or other districts [<xref rid="B1-jcm-12-02294" ref-type="bibr">1</xref>,<xref rid="B2-jcm-12-02294" ref-type="bibr">2</xref>]. The most recent research has highlighted a number of pathobiological interactions between asthma and other organs in the view of a shared immunological background underling different diseases.</p><p>An extensive knowledge of asthma comorbidities, as well as the concomitant conditions potentially worsening the asthma course or, on the other hand, that are impacted by asthma in their evolution or burden, is essential for the specialist involved in their management. In fact, the awareness of those interactions should orient the diagnostic work-up, the follow-up schedule and the identification of a personalized pharmacological and non-pharmacological action plan. In that regard, an unexpected poor response to a targeted treatment, despite the eligibility criteria being matched, might suggest the need to perform a more extensive work-up aimed at identifying potential &#8220;hidden&#8221; comorbidities. According to the currently available data, the proportion of severe asthma patients not responding to biologics ranges approximately from 10 to 25% for anti-IL-5 [<xref rid="B3-jcm-12-02294" ref-type="bibr">3</xref>,<xref rid="B4-jcm-12-02294" ref-type="bibr">4</xref>,<xref rid="B5-jcm-12-02294" ref-type="bibr">5</xref>] across different settings and specific monoclonal antibodies, which is not negligible in the light of a precision medicine approach. </p><p>The present review aims at providing an overview of the recent acquisitions in terms of asthma concomitant systemic conditions, with a special focus on the pathobiological and immunological background linking different diseases, besides the commonly known asthma respiratory comorbidities.</p></sec><sec id="sec2-jcm-12-02294"><title>2. Asthma in Eosinophilic Diseases</title><p>Bronchial asthma commonly expresses the respiratory tract involvement of eosinophil-related systemic conditions, including eosinophilic granulomatosis with polyangiitis (EGPA), allergic bronchopulmonary aspergillosis (ABPA) and hyper-eosinophilic syndrome (HES) [<xref rid="B6-jcm-12-02294" ref-type="bibr">6</xref>]. Symptoms mimicking bronchial asthma might be also part of the clinical picture of other rare eosinophilic diseases, usually involving the upper and lower airways, e.g., chronic eosinophilic pneumonia (CEP), eosinophilic bronchitis (EB) and hyper-eosinophilic obliterative bronchiolitis (HOB) [<xref rid="B7-jcm-12-02294" ref-type="bibr">7</xref>]. A proper diagnostic work-up of asthma patients, especially in the presence of elevated blood eosinophils and/or a difficult to control asthma, should always take into account the conditions mentioned above.</p><p>EGPA, previously known as Churg&#8211;Strauss syndrome, is a necrotizing granulomatous vasculitis affecting small to medium vessels [<xref rid="B8-jcm-12-02294" ref-type="bibr">8</xref>]. It is a multisystem disorder characterized by asthma, chronic rhinosinusitis and eosinophilia but also lung, cutaneous, cardiovascular, neurological and gastrointestinal involvement. The presence of eosinophilia infiltrating the internal organs and the positivity of anti-neutrophil cytoplasmic antibodies (ANCAs) are typical of the disease [<xref rid="B9-jcm-12-02294" ref-type="bibr">9</xref>]. Asthma is a central component of EGPA, representing the first of the three stages of the disease, which can overlap each other and progress at varying intervals. The first phase corresponds to asthma and allergic symptoms, followed by the phases of blood and tissue eosinophilia and finally necrotizing vasculitis [<xref rid="B10-jcm-12-02294" ref-type="bibr">10</xref>]. Asthma is also part of the six diagnostic criteria for EGPA, established by the American College of Rheumatology (ACR) [<xref rid="B11-jcm-12-02294" ref-type="bibr">11</xref>]. Severe or uncontrolled asthma is present in nearly 45% of patients at the time of diagnosis and is associated with a previous history of respiratory allergy and increased use of high-dose inhaled corticosteroids and oral corticosteroids for respiratory symptoms in the year prior to diagnosis of EGPA [<xref rid="B12-jcm-12-02294" ref-type="bibr">12</xref>].</p><p>ABPA is a complex pulmonary disorder caused by a hyper-sensitivity reaction in response to colonization of the airways with Aspergillus fumigatus. It occurs almost exclusively in patients with asthma or cystic fibrosis, which are also the predisposing conditions necessary to diagnose ABPA. The main clinical features are asthmatic symptoms, mucus plugging, pulmonary opacities, bronchiectasis, lung fibrosis, elevated blood eosinophils count and total serum IgE, and detectable serum IgE or precipitating serum antibodies against Aspergillus fumigatus or aspergillus skin test positivity [<xref rid="B13-jcm-12-02294" ref-type="bibr">13</xref>,<xref rid="B14-jcm-12-02294" ref-type="bibr">14</xref>].</p><p>In CEP, a rare lung disease characterized by systemic and local eosinophilia with bilateral lung infiltrates, the most common symptoms are a prolonged cough and dyspnoea. Most patients have also an allergic disease, such as asthma, atopic dermatitis and allergic rhinitis. In addition to systemic corticosteroids, most patients use inhaled corticosteroids since they frequently have comorbid asthma [<xref rid="B15-jcm-12-02294" ref-type="bibr">15</xref>].</p><p>HES is a group of rare disorders characterized by hyper-eosinophilia and organ damage and/or dysfunction attributable to eosinophils. Respiratory symptoms, such as a cough, dyspnoea and wheezing, are very common at presentation (25% of patients) and for this reason asthma could be frequently suspected [<xref rid="B16-jcm-12-02294" ref-type="bibr">16</xref>]. Some patients are already diagnosed with asthma, while others are diagnosed after the diagnosis of HES [<xref rid="B17-jcm-12-02294" ref-type="bibr">17</xref>]. Eosinophil-related manifestations usually are organ fibrosis, thromboembolism, cutaneous and mucosal signs and symptoms (erythema, angioedema, ulceration, pruritus and eczema) and peripheral or central neuropathy. Pulmonary involvement is common in HES and it is caused by eosinophilic infiltration of the lungs with subsequent fibrosis, heart failure or pulmonary emboli. The most common radiologic manifestations of pulmonary involvement are patchy ground-glass opacities and consolidation, but they can be various [<xref rid="B18-jcm-12-02294" ref-type="bibr">18</xref>].</p><p>EB is an airway eosinophilic inflammation characterized by eosinophilia in induced sputum, bronchoalveolar lavage (BAL) and endobronchial biopsies, in the absence of bronchial hyper-responsiveness or airflow obstruction. The main symptom is a chronic non-productive cough that responds well to inhaled corticosteroids (ICS) treatment [<xref rid="B19-jcm-12-02294" ref-type="bibr">19</xref>]. For these characteristics, EB can mimic asthma. In addition, some EB patients may develop chronic bronchial obstruction over time that would lead to the diagnosis of asthma [<xref rid="B20-jcm-12-02294" ref-type="bibr">20</xref>,<xref rid="B21-jcm-12-02294" ref-type="bibr">21</xref>].</p><p>HOB is a rare syndrome which causes chronic irreversible airflow obstruction that is unresponsive to bronchodilators or ICS. It is characterized by peripheral blood and/or BAL eosinophilia and radiological or histological evidence of bronchiolitis. This rare disease can mimic a form of severe asthma, but in some cases there appears to be an overlap with asthma, HES and other pulmonary eosinophilic diseases [<xref rid="B19-jcm-12-02294" ref-type="bibr">19</xref>,<xref rid="B22-jcm-12-02294" ref-type="bibr">22</xref>].</p></sec><sec id="sec3-jcm-12-02294"><title>3. Alpha1-Antitrypsin Deficiency</title><p>&#945;1-Antitrypsin deficiency (AATD) is a genetically determined condition that can affect several organs, leading to various clinical manifestations, including pulmonary emphysema, liver cirrhosis, vasculitis and panniculitis, which is an inflammatory skin disease. The most common clinically relevant AATD alleles are Pi*Z (Glu342Lys) and Pi*S (Glu264Val) [<xref rid="B23-jcm-12-02294" ref-type="bibr">23</xref>].</p><p>AATD occurs in approximately 1:3000&#8211;5000 people; however, it continues to be underdiagnosed in patients presenting airflow obstruction [<xref rid="B24-jcm-12-02294" ref-type="bibr">24</xref>,<xref rid="B25-jcm-12-02294" ref-type="bibr">25</xref>]. In the European population, the frequency of homozygous AATD is estimated at 0.01&#8211;0.02% [<xref rid="B26-jcm-12-02294" ref-type="bibr">26</xref>,<xref rid="B27-jcm-12-02294" ref-type="bibr">27</xref>]. Data show that less than 10% of individuals with AATD are identified and that the delay is more than 5 years between initial symptoms and diagnosis [<xref rid="B28-jcm-12-02294" ref-type="bibr">28</xref>].</p><p>The usual description of a patient with AATD as a young person with an unremarkable smoking history and end-stage emphysema is actually an uncommon presentation [<xref rid="B29-jcm-12-02294" ref-type="bibr">29</xref>]. In a study in which 965 phenotypic tests were performed in patients with airway obstruction, the mean age of subjects with the Pi*Z genotype was 55.9 &#177; 9.8 years. In another study, the average smoking history of patients with ZZ at the time of diagnosis was 23.2 &#177; 14.5 pack-years [<xref rid="B30-jcm-12-02294" ref-type="bibr">30</xref>].</p><p>AATD is frequently found in patients with asthma and, conversely, patients with AATD are more susceptible to develop asthma due to increased underlying lung inflammation, which leads asthma to coexist with AATD and emphysema [<xref rid="B31-jcm-12-02294" ref-type="bibr">31</xref>]. Furthermore, it has been recognized that allergy and asthma often coexist with AATD (<xref rid="jcm-12-02294-t001" ref-type="table">Table 1</xref>). In a study performed on patients with poorly controlled asthma, AATD was detectable in 2% to 3% of subjects, with 10.5% presenting a deficiency gene [<xref rid="B32-jcm-12-02294" ref-type="bibr">32</xref>]. An Italian study reported a non-negligible prevalence of AATD in severe asthma patients on biologic treatment; a significantly more severe lung function decline was observed in non-smoking AATD patients, suggesting AATD as a potential cause of difficult-to-control asthma in this subpopulation [<xref rid="B33-jcm-12-02294" ref-type="bibr">33</xref>]. A Spanish study that assessed the AAT distribution in an allergic asthma population reported that 22.4% of asthmatic patients had at least one mutated allele (S or Z) [<xref rid="B34-jcm-12-02294" ref-type="bibr">34</xref>]. However, no association has been found between deficient AAT genotypes or serum AATD and development of severe asthma. Moreover, no correlation between ATT levels and FEV1 was observed. Another study highlighted that AAT heterozygosity does not appear to be an important risk factor for persistent airflow limitation in patients with asthma [<xref rid="B35-jcm-12-02294" ref-type="bibr">35</xref>].</p><p>The symptoms and signs of AATD can be similar to the features of asthma, as more than 40% of patients have chronic sputum expectoration, even if they are non-smokers [<xref rid="B36-jcm-12-02294" ref-type="bibr">36</xref>]. AATD itself may predispose to airway hyper-responsiveness, but the underlying biological mechanism has not yet been clarified [<xref rid="B37-jcm-12-02294" ref-type="bibr">37</xref>]. Airway inflammation and remodeling in asthma involve degradation of the extracellular matrix, especially elastin, and are characterized by an imbalance between elastase and its primary inhibitor AAT [<xref rid="B38-jcm-12-02294" ref-type="bibr">38</xref>]. As part of the normal physiologic response to infection and inflammation, neutrophil elastase (NE) degrades extracellular matrix components in the clearance of damaged tissue and may have other antibacterial and proinflammatory effects. In healthy individuals, AAT protects alveoli from the proteolytic effects of NE by maintaining a balanced environment between anti- and pro-inflammatory proteins in the lower respiratory tract. There are several lines of evidence implicating AAT as a participant in the immune response. In addition to NE, AAT is an acute-phase reactant. Upregulation of AAT occurs in response to infection and tissue injury, in order to promote tissue repair, in a mechanism driven by interleukin-6 (IL-6) and tumor necrosis factor (TNF) [<xref rid="B29-jcm-12-02294" ref-type="bibr">29</xref>]. It has long been documented that NE is significantly increased in the induced sputum of asthma patients compared with control subjects, and NE levels in asthmatic patients correlate with a decline in FEV1 [<xref rid="B39-jcm-12-02294" ref-type="bibr">39</xref>]. However, although fixed or non-reversible obstruction in patients with asthmatic symptoms in most cases is secondary to remodeling, in some cases it may be due to the underlying AATD. In these cases, the presence of symptoms, their onset in the fourth decade, a non-reversible airway obstruction and pan-lobular (pan-acinar) emphysema should raise suspicion and promote further investigations for AATD [<xref rid="B40-jcm-12-02294" ref-type="bibr">40</xref>].</p><p>Patients diagnosed with AATD who have coexisting asthma need treatments aimed at reducing bronchial hyper-responsiveness and inflammation. Pneumococcal and influenza vaccinations significantly reduce the frequency of exacerbations in patients with AATD. Moreover, annual lung function assessments, pulmonary rehabilitation, liver disease screening, improving nutrition and the use of supplemental oxygen are important management tools. Clinical evidence has indicated positive effects on lung physiology with augmentation therapy, which can stabilize lung function and slow further lung destruction [<xref rid="B29-jcm-12-02294" ref-type="bibr">29</xref>,<xref rid="B41-jcm-12-02294" ref-type="bibr">41</xref>].</p><table-wrap position="anchor" id="jcm-12-02294-t001" orientation="portrait"><object-id pub-id-type="pii">jcm-12-02294-t001_Table 1</object-id><label>Table 1</label><caption><p>Main distinguishing features of asthma and &#945;1-Antitrypsin deficiency (AATD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Asthma</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AATD</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Prevalence</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3&#8211;9% [<xref rid="B42-jcm-12-02294" ref-type="bibr">42</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#8211;3% [<xref rid="B33-jcm-12-02294" ref-type="bibr">33</xref>,<xref rid="B38-jcm-12-02294" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Onset</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Variable,<break/>childhood &gt; adulthood [<xref rid="B42-jcm-12-02294" ref-type="bibr">42</xref>,<xref rid="B43-jcm-12-02294" ref-type="bibr">43</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40&#8211;53 ys,<break/>Adulthood &gt; childhood [<xref rid="B38-jcm-12-02294" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Family history</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Allergic diseases (atopic eczema, allergic rhinitis, asthma, food allergies) [<xref rid="B42-jcm-12-02294" ref-type="bibr">42</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asthma, emphysema, liver cirrhosis, vasculitis [<xref rid="B40-jcm-12-02294" ref-type="bibr">40</xref>,<xref rid="B41-jcm-12-02294" ref-type="bibr">41</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Lung function test (PFTs)</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Airway hyper-responsiveness, reversible obstruction [<xref rid="B42-jcm-12-02294" ref-type="bibr">42</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fixed or nonreversible obstruction [<xref rid="B40-jcm-12-02294" ref-type="bibr">40</xref>,<xref rid="B41-jcm-12-02294" ref-type="bibr">41</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Concomitant allergies</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70% [<xref rid="B42-jcm-12-02294" ref-type="bibr">42</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22% [<xref rid="B43-jcm-12-02294" ref-type="bibr">43</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Diagnosis</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical history, physical examination, PFTs, demonstration of reversible obstruction [<xref rid="B42-jcm-12-02294" ref-type="bibr">42</xref>,<xref rid="B43-jcm-12-02294" ref-type="bibr">43</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Genetic testing, and phenotype testing [<xref rid="B38-jcm-12-02294" ref-type="bibr">38</xref>,<xref rid="B43-jcm-12-02294" ref-type="bibr">43</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Therapy</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICS, LABA, LAMA, montelukast, Biologics [<xref rid="B42-jcm-12-02294" ref-type="bibr">42</xref>,<xref rid="B43-jcm-12-02294" ref-type="bibr">43</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">As asthma + AAT augmentation therapy [<xref rid="B38-jcm-12-02294" ref-type="bibr">38</xref>,<xref rid="B43-jcm-12-02294" ref-type="bibr">43</xref>]</td></tr></tbody></table></table-wrap></sec><sec id="sec4-jcm-12-02294"><title>4. Immunodeficiencies</title><p>Immunodeficiencies are conditions characterized by a defective immune system functioning which leads to increased susceptibility to infections, cancer and autoimmunity. Common Variable Immunodeficiency (CVID) is the prototype of these conditions being the most common symptomatic primary immunodeficiency (PID).</p><p>The presence of an immune deficiency in an asthma patient increases the burden of the disease, leading to poorer symptom control, higher exacerbation rates and impaired lung function over time [<xref rid="B44-jcm-12-02294" ref-type="bibr">44</xref>].</p><p>Asthmatic patients have an increased risk (OR 2.46&#8211;4.98) of having an antibody deficiency compared to those without a history of asthma [<xref rid="B45-jcm-12-02294" ref-type="bibr">45</xref>] and in CVID patients, asthma is the most common respiratory complication [<xref rid="B46-jcm-12-02294" ref-type="bibr">46</xref>]. The reason underneath this association is still poorly understood, although there is probably a role played by corticosteroid therapy, a well-known cause of secondary immunodeficiency [<xref rid="B47-jcm-12-02294" ref-type="bibr">47</xref>].</p><p>The coexistence of asthma and immunodeficiency determines a worse prognosis, as demonstrated by a recent study which showed that asthmatic patients with PIDs more frequently have a severe condition and frequent exacerbations [<xref rid="B48-jcm-12-02294" ref-type="bibr">48</xref>].</p><p>A compromised immune system leads to an increase in respiratory infections, which in turn are triggers for asthma exacerbation [<xref rid="B49-jcm-12-02294" ref-type="bibr">49</xref>]. Therefore, if frequent exacerbations are present, the clinician must pay particular attention and request additional tests (i.e., Ig dosage and test vaccine response) in order to identify a possible underlying immunodeficiency. Another subgroup of particular interest is non-type two asthma with low serum eosinophils and fractional exhaled nitric oxide (FeNO), as these patients more frequently present an antibody deficiency [<xref rid="B50-jcm-12-02294" ref-type="bibr">50</xref>].</p><p>In asthmatic patients with immunodeficiency, the use of immunoglobulin replacement therapy (IRT) or prophylactic antibiotic therapy has been proposed with good results [<xref rid="B44-jcm-12-02294" ref-type="bibr">44</xref>,<xref rid="B49-jcm-12-02294" ref-type="bibr">49</xref>]. In a recent study, Tiotiu and colleagues showed that IRT and prophylactic azithromycin were able to reduce the number of infection-driven exacerbations, increase asthma control and improve lung function. Moreover, patients who do not respond to azithromycin may benefit from IRT, opening up the possibility of a sequential approach [<xref rid="B44-jcm-12-02294" ref-type="bibr">44</xref>]. IRT has also been studied in patients with severe asthma without an antibody deficiency, but failed to show a significative improvement, highlighting the importance of careful patient selection alongside consideration of the high cost [<xref rid="B51-jcm-12-02294" ref-type="bibr">51</xref>].</p><p>To date, it is not completely clear whether the primum movens is asthma or immunodeficiency; probably, both conditions represent a fertile ground where the other can develop and they act synergically in worsening the patient&#8217;s condition. The possible presence of an immunodeficiency in asthmatic patients is an issue that must be addressed, especially in the presence of certain features/red flags, in order to increase disease control, improve quality of life and avoid complications.</p></sec><sec id="sec5-jcm-12-02294"><title>5. Sickle Cell Disease</title><p>Sickle cell disease (SCD) is the most common worldwide distributed monogenic red cell disorder, which still has high mortality and morbidity. The main clinical manifestations of SCD are chronic hemolytic anemia and acute vaso-occlusive crisis (VOCs) [<xref rid="B52-jcm-12-02294" ref-type="bibr">52</xref>,<xref rid="B53-jcm-12-02294" ref-type="bibr">53</xref>]. These are the major causes of hospitalization in both pediatric and adult patients with SCD. Recent progresses in pathophysiologic understanding of SCD have highlighted the key role of sustained oxidation and chronic inflammation associated with increased pro-inflammatory cytokines (e.g., IL-1b, IL-6 and endothelin-1 (ET-1)) in the generation of VOCs. In addition, the unbalance between pro-inflammatory and pro-resolving mechanisms promotes inflammatory vasculopathy and disease progression [<xref rid="B54-jcm-12-02294" ref-type="bibr">54</xref>,<xref rid="B55-jcm-12-02294" ref-type="bibr">55</xref>]. The biocomplexity of SCD is further increased by the local relative reduction in nitric oxide bioavailability, contributing to abnormal vascular tone and to a plasma pro-oxidant environment [<xref rid="B55-jcm-12-02294" ref-type="bibr">55</xref>,<xref rid="B56-jcm-12-02294" ref-type="bibr">56</xref>,<xref rid="B57-jcm-12-02294" ref-type="bibr">57</xref>]. Lungs are one of the target organs of SCD due to the peculiarity of the vascular bed where deoxygenated sickle red cells transit [<xref rid="B58-jcm-12-02294" ref-type="bibr">58</xref>]. In addition, non-genetic modifiers targeting lung have been shown to contribute to sickle cell related pulmonary manifestations such as air quality, weather (e.g., humidity, wind speed or temperature), smoking or infections [<xref rid="B59-jcm-12-02294" ref-type="bibr">59</xref>].</p><p>A broad spectrum of lung clinical manifestations, such as acute chest syndrome (ACS), asthma and recurrent wheezing, venous thromboembolic disease and sleep-disordered breathing, commonly coexist with SCD [<xref rid="B60-jcm-12-02294" ref-type="bibr">60</xref>]. The association between asthma and SCD has long since been recognized; however, the frequent wheezing that characterizes SCD patients may perhaps account for overdiagnosis of asthma in such a condition [<xref rid="B61-jcm-12-02294" ref-type="bibr">61</xref>]. Of note is that the presence of wheezing, even in the absence of an asthma diagnosis, has been recently proposed as a risk factor for the severity of sickle cell related clinical manifestations [<xref rid="B62-jcm-12-02294" ref-type="bibr">62</xref>]. This is of interest since children with SCD and asthma have increased rates of VOCs and ACS and have an increased risk of premature death [<xref rid="B61-jcm-12-02294" ref-type="bibr">61</xref>,<xref rid="B63-jcm-12-02294" ref-type="bibr">63</xref>]. Epidemiologic studies report a higher prevalence of asthma in the SCD population compared to matched healthy controls. However, the small group size, patients&#8217; heterogeneity and the lack of a standardized diagnostic approach are the major limitations of these studies. These factors justify the presence of few contradictory results on the prevalence of asthma in patients with SCD [<xref rid="B64-jcm-12-02294" ref-type="bibr">64</xref>,<xref rid="B65-jcm-12-02294" ref-type="bibr">65</xref>]. In this scenario, the design of population-based studies comparing SCD patients and healthy control subjects in terms of asthma incidence and prevalence are required to drive consistent conclusions on asthma in SCD, particularly considering that recurrent wheezing is a common feature in patients with SCD, even without a personal or familiar asthma history. In a study on 939 patients experiencing ACS, 11% of them presented with wheezing on admission to the hospital [<xref rid="B61-jcm-12-02294" ref-type="bibr">61</xref>]. Similar findings have been confirmed by different research groups, describing an equally common wheezing presentation of ACS among children and adults [<xref rid="B66-jcm-12-02294" ref-type="bibr">66</xref>,<xref rid="B67-jcm-12-02294" ref-type="bibr">67</xref>]. Notably, severe wheezing, regardless of the presence of underlying asthma, was reported to double the rates of pain and ACS, decrease lung function and increase risk of death [<xref rid="B68-jcm-12-02294" ref-type="bibr">68</xref>,<xref rid="B69-jcm-12-02294" ref-type="bibr">69</xref>].</p><p>Different factors have been suggested to contribute to airways obstruction in SCD, such as increased Th2 response and pulmonary vascular engorgement due to the presence of dense, sticky red cells, overactivated neutrophils and inflammatory vasculopathy [<xref rid="B70-jcm-12-02294" ref-type="bibr">70</xref>]. This mediates abnormal gas exchange leading to bronchoconstriction-induced ventilation&#8211;perfusion mismatch and tissue hypoxia associated with increased small airway &#8220;compression&#8221; and resistance. The presence of high pulmonary ET-1 expression combined with reduced NO bioavailability and autonomic dysfunction has been proposed to play a key role in increased airway hyper-reactivity observed in patients with SCD [<xref rid="B71-jcm-12-02294" ref-type="bibr">71</xref>]. Some of these features are shared by asthma as well as endothelial disfunction, which is also a key element in the pathogenesis of obstructive pulmonary diseases [<xref rid="B72-jcm-12-02294" ref-type="bibr">72</xref>].</p><p>Asthma impacts on SCD patients differently from the general population; thus, the investigation of signs and symptoms of asthma (or asthma-like diseases) in SCD should be part of the comprehensive care of subjects with SCD, in particular for children and adolescent populations [<xref rid="B62-jcm-12-02294" ref-type="bibr">62</xref>,<xref rid="B70-jcm-12-02294" ref-type="bibr">70</xref>]. This will allow us to early intercept patients at risk of developing a severe clinical phenotype. Whenever a diagnosis of asthma is confirmed, clinical management should be based on international recommendations and guidelines, including inhaled corticosteroids and bronchodilator treatments according to asthma severity grade. The use of systemic corticosteroids should be carefully evaluated as they are associated with an increased risk of rebounding SCD-related pain on withdrawal and avascular necrosis especially in SCD patients [<xref rid="B60-jcm-12-02294" ref-type="bibr">60</xref>,<xref rid="B73-jcm-12-02294" ref-type="bibr">73</xref>,<xref rid="B74-jcm-12-02294" ref-type="bibr">74</xref>]. New biologic therapies might be considered and discussed case by case in a multidisciplinary team, as they could allow for better asthma control and lower steroid use.</p></sec><sec id="sec6-jcm-12-02294"><title>6. Neurodegenerative Diseases</title><p>In recent years, several studies revealed an intriguing relationship between asthma and brain involvement [<xref rid="B75-jcm-12-02294" ref-type="bibr">75</xref>,<xref rid="B76-jcm-12-02294" ref-type="bibr">76</xref>,<xref rid="B77-jcm-12-02294" ref-type="bibr">77</xref>,<xref rid="B78-jcm-12-02294" ref-type="bibr">78</xref>,<xref rid="B79-jcm-12-02294" ref-type="bibr">79</xref>,<xref rid="B80-jcm-12-02294" ref-type="bibr">80</xref>,<xref rid="B81-jcm-12-02294" ref-type="bibr">81</xref>]. Mild cognitive impairment (MCI) was the most frequently reported disease, though dementia (D) and Alzheimer Disease (AD) were also associated with asthma, but to a lesser extent. In these epidemiological studies, older age, uncontrolled and more severe asthma were identified as risk factors for brain involvement, but several studies confirmed this association even at a younger age and in patients with mild asthma [<xref rid="B82-jcm-12-02294" ref-type="bibr">82</xref>]. A bidirectional interaction between asthma and extra-respiratory systemic diseases has been recently demonstrated. In fact, in a subgroup of patients with more severe asthma, a significant relationship with concomitant hyper-tension and metabolic syndrome has been revealed, the increase in interleukin-6 (IL-6) being the hallmark of this group of patients [<xref rid="B83-jcm-12-02294" ref-type="bibr">83</xref>]. Bronchial asthma can negatively affect metabolic diseases, such as diabetes or vascular diseases, even at a early age [<xref rid="B84-jcm-12-02294" ref-type="bibr">84</xref>,<xref rid="B85-jcm-12-02294" ref-type="bibr">85</xref>]. The drop in oxygen saturation, which can complicate asthma exacerbations, has been indicated as being responsible for neural involvement. Neural changes due to hypoxia might translate into neuronal damage, particularly in regions of high metabolic demand [<xref rid="B82-jcm-12-02294" ref-type="bibr">82</xref>]. However, MCI has also been found in mild asthma and no correlation has been proved between the frequency of exacerbations and neural involvement. More recently, asthma-associated inflammation has also been recognized as responsible for inflammation of the central nervous system leading to glial activation and eventually cognitive impairment. A recent study identified a significant increase in astrocytes activation markers, as GFAP (Glial Fibrillary Acid protein) and NfL (Neurofilament Light Chain), which was significantly related to asthma severity. In the same study on asthmatics, differences have been found in several metrics of diffusion-weighted magnetic resonance imaging (MRI), suggestive of neuroinflammation and neurodegeneration, but no correlation has been found between T2 and neural inflammation biomarkers [<xref rid="B86-jcm-12-02294" ref-type="bibr">86</xref>]. However, concomitant treatment with biologics or steroids may have influenced this result. Furthermore, using functional MRI after a specific allergen challenge, asthmatic patients who presented a late response displayed a different activation of the anterior insular cortex in comparison to healthy controls and patients with mild asthma, suggesting the existence of different neurophenotypes in asthma [<xref rid="B87-jcm-12-02294" ref-type="bibr">87</xref>]. Likewise, in younger asthmatics a significant reduction of the metabolites, such as N-acetyl aspartate, glutamate, creatine and myo-inositol, from hippocampus was detected, indicating neural viability, reduced energy reserve and glial activation. It has been hypothesized that this alteration might precede the subsequent MCI at an older age [<xref rid="B88-jcm-12-02294" ref-type="bibr">88</xref>]. In the relationship between asthma and the central nervous system, the role of the treatment must be considered. One study showed that a prolonged use of oral corticosteroids reduced the volume of the amygdala, which is a brain structure involved in the emotional pathway and plays an important role in the response to stress [<xref rid="B89-jcm-12-02294" ref-type="bibr">89</xref>]. On the other hand, inhaled steroids proved to have a protective role in animal models as well as in humans whereas the exclusive use of bronchodilators has a negative impact on brain involvement, probably due to the risk of uncontrolled asthma [<xref rid="B82-jcm-12-02294" ref-type="bibr">82</xref>]. In addition, montelukast has been found to have a protective role against damage to the nervous system in animal models [<xref rid="B90-jcm-12-02294" ref-type="bibr">90</xref>]. Though the association between asthma and nervous system involvement must be confirmed by further studies and its mechanisms clarified, current data might have potential social implication. MCI, dementia and AD are common diseases in older age and, notably, no treatment is currently available. They can negatively also affect the management of concomitant diseases, strongly reducing the adherence to their treatment. Therefore, a prompt identification of an initial brain involvement could be vital in term of prevention and progression of these diseases.</p></sec><sec id="sec7-jcm-12-02294"><title>7. Metabolic Syndrome and Obesity</title><p>Metabolic syndrome consists of a cluster of risk factors that increase the chance of developing heart disease, strokes and type 2 diabetes. These conditions include increased blood pressure, high blood glucose, excess body fat around the waist and abnormal HDL cholesterol or triglyceride levels. The prevalence of metabolic syndrome among patients with asthma is estimated to be 25% [<xref rid="B91-jcm-12-02294" ref-type="bibr">91</xref>]. A recent study has shown that metabolic syndrome is more prevalent in asthma patients compared to controls, and that the onset of asthma in adulthood is associated with metabolic syndrome, even when adjusted for age, sex, body mass index and smoking history [<xref rid="B92-jcm-12-02294" ref-type="bibr">92</xref>]. Among the components of metabolic syndrome, two are mainly associated with an increased risk of incident asthma in adults: high waist circumference and elevated glucose or diabetes.</p><p>According to the HUNT study, a prospective cohort study, patients with hyper-glycaemia or type two diabetes mellitus have a higher incidence of asthma (OR 1.43, 95% CI 1.01&#8211;2.04) over an average of 11 years of follow-up [<xref rid="B93-jcm-12-02294" ref-type="bibr">93</xref>]. Higher glycated haemoglobin (HbA1c) is associated with a higher asthma exacerbation rate compared with individuals with normal HbA1c: patients in the prediabetes range have a 27% higher rate and those in the diabetes range have a 33% higher rate [<xref rid="B94-jcm-12-02294" ref-type="bibr">94</xref>]. In addition, HbA1c level in the pre-diabetes/diabetes range is associated with a higher rate of asthma hospitalization and inversely related to respiratory function parameters, such as FEV1 and FVC [<xref rid="B95-jcm-12-02294" ref-type="bibr">95</xref>]. Among the mechanisms underlying the association between asthma and diabetes, insulin resistance appears to play an important role leading to airway disfunction [<xref rid="B96-jcm-12-02294" ref-type="bibr">96</xref>]. In fact, hyper-insulinemia associated with insulin resistance is associated with the proliferation of airway smooth muscle and promotes its contractility [<xref rid="B97-jcm-12-02294" ref-type="bibr">97</xref>].</p><p>Hyper-tension is associated with worse morbidity and outcomes in asthma, although there are few studies supporting this association [<xref rid="B2-jcm-12-02294" ref-type="bibr">2</xref>]. A large study reported that hyper-tension correlated with greater odds of rescue inhaler use, emergency department visits or hospitalizations, and corticosteroid use [<xref rid="B98-jcm-12-02294" ref-type="bibr">98</xref>]. Hyper-tension and asthma share some immune mechanisms in their pathogenesis, especially for non-type two asthma. Angiotensin II is a vasopressor that induces secretion of IL-17A, which blocks vasodilation induced by endothelial-derived nitric oxide [<xref rid="B2-jcm-12-02294" ref-type="bibr">2</xref>]. IL-17A seems to play a key role because IL-17A knock-out mice do not experience prolonged hyper-tension [<xref rid="B99-jcm-12-02294" ref-type="bibr">99</xref>], and, on the other hand, this cytokine contributes to airway hyper-responsiveness in mice [<xref rid="B100-jcm-12-02294" ref-type="bibr">100</xref>] and is elevated in bronchoalveolar lavage fluid of severe asthma patients [<xref rid="B101-jcm-12-02294" ref-type="bibr">101</xref>]. For this reason, angiotensin receptor blockers have been evaluated as a dual treatment for both asthma and hyper-tension [<xref rid="B102-jcm-12-02294" ref-type="bibr">102</xref>].</p><p>Regarding elevated blood lipid levels, several studies have been conducted on adult patients with asthma with conflicting results [<xref rid="B103-jcm-12-02294" ref-type="bibr">103</xref>,<xref rid="B104-jcm-12-02294" ref-type="bibr">104</xref>,<xref rid="B105-jcm-12-02294" ref-type="bibr">105</xref>]. A large meta-analysis revealed that levels of low-density lipoprotein (LDL) and total cholesterol were higher in patients with asthma than controls, but there was no association between asthma and levels of high-density lipoprotein (HDL) or triglycerides [<xref rid="B106-jcm-12-02294" ref-type="bibr">106</xref>]. A recent study showed that triglycerides were statistically significantly higher in patients with obesity and asthma adjusted for body mass index (BMI), blood eosinophils and statin use [<xref rid="B107-jcm-12-02294" ref-type="bibr">107</xref>]. In addition to regulation of cholesterol metabolism, the anti-inflammatory properties of statins are believed to play a role in asthma control [<xref rid="B108-jcm-12-02294" ref-type="bibr">108</xref>,<xref rid="B109-jcm-12-02294" ref-type="bibr">109</xref>]. In a recent case-control study, statin use was associated with a reduced risk of asthma-related emergency department visits, hospitalizations and systemic steroid use in patients with asthma [<xref rid="B110-jcm-12-02294" ref-type="bibr">110</xref>].</p><p>There is a complex interrelationship that links asthma to obesity. Asthma prevalence among obese patients is increased compared to the general population and data show that 20&#8211;50% of severe asthmatic patients are obese, with female patients at higher risk. The reasons underlying such interplay are not fully understood but genetic, dietary, environmental and immune factors are thought to play a major role in the pathogenesis of both conditions with an emerging role of the gut microbiome [<xref rid="B111-jcm-12-02294" ref-type="bibr">111</xref>].</p><p>Traditionally, asthmatic&#8211;obese patients were considered to have a specific disease pheno-endotype characterized by neutrophilic inflammation, lower allergic burden, less airway hyper-responsiveness and worse response to inhaled therapy. To date, the picture is more complex as various asthma phenotypes have been identified in the obese population, although usually with a consistent Th1 fingerprint [<xref rid="B112-jcm-12-02294" ref-type="bibr">112</xref>].</p><p>What is ascertained is that the association between asthma and obesity determines worse symptom control, reduced response to inhaled therapy and higher exacerbation and hospitalization rates [<xref rid="B111-jcm-12-02294" ref-type="bibr">111</xref>]. Different mechanisms play a role in the aggravation of the clinical condition in asthmatic&#8211;obese patients. First of all, the increased thoracic and abdominal adipose tissue reduces pulmonary expansion adding a restrictive component to lung functional impairment; secondly, the increased systemic inflammatory status that characterizes obese patients leads to higher airway obstruction and reduced response to corticosteroids [<xref rid="B113-jcm-12-02294" ref-type="bibr">113</xref>]. Not only obesity itself, but also comorbidities typically associated with obesity are involved in the aggravation of asthma symptoms: obese patients are more likely to have metabolic syndrome and suffer from obstructive sleep apnoea syndrome, GERD and depression [<xref rid="B42-jcm-12-02294" ref-type="bibr">42</xref>].</p><p>The approach to therapy is particularly delicate in obese&#8211;asthmatic patients, who are said to be less likely to be adequately controlled by standard inhaled therapy. The use of long-term systemic corticosteroids should be avoided given the already high burden of metabolic comorbidities in such patients. Concerns rise for biologic therapies as well, since absorption and distribution are probably altered and standard dosage could be insufficient to have a therapeutic effect in obese patients, as this happens in other diseases [<xref rid="B114-jcm-12-02294" ref-type="bibr">114</xref>]. Moreover, it is possible that traditional biomarkers would not be appropriate in this population and lower thresholds, for example for eosinophils, have been proposed to identify specific inflammatory patterns [<xref rid="B115-jcm-12-02294" ref-type="bibr">115</xref>].</p><p>In conclusion, asthma in obese patients should be considered as a different and more complex disease when compared to asthma in non-obese patients. It is characterized by respiratory and systemic additional cofactors and comorbidities that make both endotypization and phenotypization more complex and less efficacious, and therefore it needs an integrated diagnostic and therapeutic approach.</p></sec><sec id="sec8-jcm-12-02294"><title>8. Cardiovascular Disease</title><p>Beyond their own phenotypic characteristics and differences, both asthma and atherosclerosis are chronic inflammatory diseases in which the pathways and the effectors of the inflammatory response play a crucial role. Atherosclerosis, the leading histopathologic ground of cardiovascular disease (CVD), is per se a low-grade chronic inflammatory condition and not only a lipoprotein-driven disease [<xref rid="B116-jcm-12-02294" ref-type="bibr">116</xref>]. Lymphocytes, monocytes, macrophages and neutrophils are important participants at the various stages of CVD progression, from early development to late complications of atherosclerotic plaques [<xref rid="B117-jcm-12-02294" ref-type="bibr">117</xref>,<xref rid="B118-jcm-12-02294" ref-type="bibr">118</xref>]. Noteworthy from a therapeutic point of view is the importance of inflammation in CVD, which has been further emphasized by the proof-of-concept CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) trial, which showed that anti-inflammatory treatments&#8212;in that case, the pharmacological inhibition of interleukin-1beta&#8212;may reduce cardiovascular risk independently of lipoprotein-mediated mechanisms [<xref rid="B119-jcm-12-02294" ref-type="bibr">119</xref>]. However, the association between inflammation and CVD may go beyond the &#8220;classic&#8221; inflammatory pathways. Recent evidence addressed the interest in allergic inflammation and its cellular effectors, such as mast cells, eosinophils and basophils [<xref rid="B120-jcm-12-02294" ref-type="bibr">120</xref>,<xref rid="B121-jcm-12-02294" ref-type="bibr">121</xref>].</p><p>In mice models, several studies indicated that mast cells may promote atherosclerosis by releasing proinflammatory cytokines. Mast cell-deficient mice were protected from the development of atherosclerosis when crossbred with low-density lipoprotein receptor (LDLR)-deficient mice [<xref rid="B122-jcm-12-02294" ref-type="bibr">122</xref>] and failed to develop abdominal aortic aneurysms induced by elastase perfusion or periaortic chemical injury [<xref rid="B123-jcm-12-02294" ref-type="bibr">123</xref>]. On the other hand, the activation of mast cells in wild type mice resulted in enhanced abdominal aortic aneurysms growth, while mast cell stabilization with disodium cromoglycate diminished abdominal aortic aneurysms formation [<xref rid="B123-jcm-12-02294" ref-type="bibr">123</xref>]. Pharmacological stabilization of mast cells by means of disodium cromoglycate attenuated experimental atherogenesis in LDLR-deficient mice [<xref rid="B124-jcm-12-02294" ref-type="bibr">124</xref>], while the mast cells stabilizer cromolyn markedly decreased the rupture rate of aneurysms in adult mice with induced intracranial aneurysms [<xref rid="B125-jcm-12-02294" ref-type="bibr">125</xref>]. According to this experimental evidence, pharmacological inhibition of mast cell activation has been hypothesized to offer new therapeutic strategies aiming to reduce cardiovascular risk in humans [<xref rid="B120-jcm-12-02294" ref-type="bibr">120</xref>].</p><p>Eosinophil-deficient mice had also decreased atherosclerotic lesion burden as compared with littermate controls when crossbred with apolipoprotein E (Apo E)-deficient mice. Eosinophils have been shown to contribute to atherosclerotic lesion formation by activating endothelial cells, as well as to support arterial thrombosis by propagating platelet accumulation [<xref rid="B126-jcm-12-02294" ref-type="bibr">126</xref>]. In humans, genome-wide association studies (GWAS) showed that sequence variants affecting eosinophil numbers were associated not only with asthma but also with myocardial infarction [<xref rid="B127-jcm-12-02294" ref-type="bibr">127</xref>]. Eosinophil blood count has been proposed as a potential predictor of cardiovascular risk [<xref rid="B128-jcm-12-02294" ref-type="bibr">128</xref>,<xref rid="B129-jcm-12-02294" ref-type="bibr">129</xref>] and a recent large cohort study within the framework of the Rochester Epidemiology Project confirmed that high eosinophil blood counts were associated with an increased risk of cardiovascular events, including heart failure, stroke and cardiovascular death [<xref rid="B130-jcm-12-02294" ref-type="bibr">130</xref>]. Moreover, eosinophil degranulation and activation have been linked with coronary instability and a worse clinical outcome after acute myocardial infarction [<xref rid="B131-jcm-12-02294" ref-type="bibr">131</xref>].</p><p>Few biochemical and clinical clues have suggested a role for basophils in CVD so far. Nonetheless, basophil activation was higher in subjects with acute coronary syndrome than in those with stable angina [<xref rid="B131-jcm-12-02294" ref-type="bibr">131</xref>]. Within the framework of the angiographically controlled Verona Heart Study cohort, basophil blood counts predicted mortality in patients with clinically stable coronary artery disease, with high cell counts associated with an increased risk of total and cardiovascular mortality. Additionally, high basophil blood counts were associated with enhanced factor II plasma coagulant activity, thereby suggesting an underlying prothrombotic diathesis [<xref rid="B132-jcm-12-02294" ref-type="bibr">132</xref>]. Notably, basophils can release extracellular DNA traps facilitating coagulation activation and thrombus formation [<xref rid="B133-jcm-12-02294" ref-type="bibr">133</xref>], while basophil granules contain polyphosphate, which is recognized as a procoagulant player in haemostasis [<xref rid="B134-jcm-12-02294" ref-type="bibr">134</xref>,<xref rid="B135-jcm-12-02294" ref-type="bibr">135</xref>].</p><p>Therefore, the cellular effectors of allergic inflammation, such as mast cells, eosinophils and basophiles, could be a potential pathogenic link between asthma and CVD.</p><p>In line with these observations and consistent with the potential role of allergic inflammation in CVD, several epidemiological studies showed an increase in cardiovascular risk in patients with asthma, although with some controversial results [<xref rid="B136-jcm-12-02294" ref-type="bibr">136</xref>]. Asthma has been associated with endothelial dysfunction [<xref rid="B137-jcm-12-02294" ref-type="bibr">137</xref>], prothrombotic diathesis [<xref rid="B138-jcm-12-02294" ref-type="bibr">138</xref>], myocardial infarction [<xref rid="B139-jcm-12-02294" ref-type="bibr">139</xref>] and cardiovascular mortality [<xref rid="B140-jcm-12-02294" ref-type="bibr">140</xref>,<xref rid="B141-jcm-12-02294" ref-type="bibr">141</xref>]. Asthma has been associated with atherosclerotic artery changes independent of traditional cardiovascular risk factors [<xref rid="B84-jcm-12-02294" ref-type="bibr">84</xref>] and with ischemic heart disease independent of pharmacological therapies [<xref rid="B142-jcm-12-02294" ref-type="bibr">142</xref>]. A very recent meta-analysis confirmed that asthma patients have an increased risk of CVD morbidity and mortality [<xref rid="B143-jcm-12-02294" ref-type="bibr">143</xref>]. Allergic asthma aggravated atherosclerosis even in Apo E-deficient mice models, where a potential influence on cholesterol metabolism was also detected [<xref rid="B144-jcm-12-02294" ref-type="bibr">144</xref>].</p><p>According to some evidence, asthma patients present an increased risk of right heart dysfunction as well. The first report dates back to early 20th century when right heart-related electrocardiographic alterations were described in acute bronchial asthma by different research groups [<xref rid="B145-jcm-12-02294" ref-type="bibr">145</xref>]. Of note, such alterations resolved after the resolution of the asthmatic attack. The effects of asthma on right heart functioning were highlighted outside the acute attack as well, as demonstrated by a recent study on 55 patients with mild&#8211;moderate asthma which showed the presence of subclinical right heart impairment derived from abnormal echocardiographic parameters [<xref rid="B146-jcm-12-02294" ref-type="bibr">146</xref>]. It is not surprising if we consider the vasoconstrictive response and remodeling of pulmonary arterioles secondary to hypoxia and followed by increased vascular resistance. It may lead to pulmonary hyper-tension and eventually upstream right heart disfunction due to the enhanced right ventricle afterload [<xref rid="B147-jcm-12-02294" ref-type="bibr">147</xref>]. Such changes seem to correlate with asthma severity and develop early in the disease course; in fact, they can be detected in asthmatic children who have been shown to have increased right ventricle wall thickness [<xref rid="B148-jcm-12-02294" ref-type="bibr">148</xref>] as well as significantly different right heart related echocardiographic parameters and NT-pro BNP blood levels, when compared to healthy controls [<xref rid="B149-jcm-12-02294" ref-type="bibr">149</xref>].</p><p>Such findings highlight that asthma has a deep impact on right heart function as well, particularly on diastolic function, being responsible for both acute and chronic/progressive alterations which should be carefully assessed when evaluating patients. Echocardiography, when performed by trained clinicians able to appraise specific right heart-related parameters, is the most accessible screening tool, along with laboratory markers such as NT-proBNP, which improves the diagnostic accuracy. An early diagnosis, intercepting the subclinical phase when alterations are still entirely or partially reversible, should not be neglected in asthma patients of any age.</p><p>From a therapeutic perspective, when considering that inflammation is the most important underlying mechanism in asthma, anti-inflammatory therapies including steroids or biologicals seem to be relevant in preventing damage and disease progression, although data are still scarce [<xref rid="B150-jcm-12-02294" ref-type="bibr">150</xref>].</p><p>In summary, taking into account all this clinical and experimental evidence, it is tempting to speculate that it may be time to rethink both the role of allergic inflammation in atherothrombosis and the link between asthma and CVD. From a pathobiological point of view, allergic inflammation pathways may be relevant in the development, progression and complications of atherosclerosis and in both left and right heart function impairment. Patients with asthma may have an increased cardiovascular risk and clinicians should be aware of this issue. Finally, in perspective, a more thorough knowledge of inflammatory pathways in CVD may both (i) pave the way to new therapies for reducing the residual cardiovascular risk and (ii) lead to more efficient treatment strategies for improving overall survival and quality of life in asthma patients.</p></sec><sec sec-type="conclusions" id="sec9-jcm-12-02294"><title>9. Conclusions</title><p>In the era of a personalized approach to patients, the availability of different precision medicine options is not enough. In fact, the effective use of targeted treatments does not allow for covering the complex interplay of concomitant conditions potentially coexisting in each patient. On the other hand, the recent insights coming from the translational and pharmacological research have revealed more than one pathobiological connection, linking different conditions and pleiotropic clinical manifestations (<xref rid="jcm-12-02294-f001" ref-type="fig">Figure 1</xref>). Under that perspective, every clinician managing asthma patients, or individuals affected by conditions which may hamper the achievement of asthma control or whose burden may be negatively impacted by coexisting asthma, should be aware of those interactions and tailor his or her clinical approach accordingly. In other terms, from the diagnostic work to the identification of the best combination of targeted treatments, ordinary therapy and a non-pharmacological approach as well as an extensive knowledge of the link between apparently different diseases and their common immunological background is essential.</p><p>The relevance of that acquisition is of the utmost importance in the management of asthma patients and paves the way to a new approach in the light of a personalized medicine perspective.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization and methodology, M.C., M.M. and G.S.; data search and original draft preparation, M.M., B.O., G.G., L.D.F., N.M., R.V., G.S., G.A. and M.C.; writing&#8212;review and editing, M.C., G.S., G.A. and L.D.F.; supervision, G.S., A.V. and M.C. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-jcm-12-02294"><label>1.</label><element-citation publication-type="webpage"><article-title>The Global Initiative for Asthma</article-title><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ginasthma.org/reports/" ext-link-type="uri">https://ginasthma.org/reports/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-28">(accessed on 28 December 2022)</date-in-citation></element-citation></ref><ref id="B2-jcm-12-02294"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cardet</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Bulkhi</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Lockey</surname><given-names>R.F.</given-names></name></person-group><article-title>Nonrespiratory Comorbidities in Asthma</article-title><source>J. Allergy Clin. Immunol. Pract.</source><year>2021</year><volume>9</volume><fpage>3887</fpage><lpage>3897</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2021.08.027</pub-id><pub-id pub-id-type="pmid">34492402</pub-id><pub-id pub-id-type="pmcid">PMC8631133</pub-id></element-citation></ref><ref id="B3-jcm-12-02294"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caminati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Senna</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stefanizzi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bellamoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Longhi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chieco-Bianchi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Guarnieri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tognella</surname><given-names>S.</given-names></name><name name-style="western"><surname>Olivieri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Micheletto</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience</article-title><source>BMC Pulm. Med.</source><year>2016</year><volume>16</volume><elocation-id>128</elocation-id><pub-id pub-id-type="doi">10.1186/s12890-016-0290-5</pub-id><pub-id pub-id-type="pmid">27562427</pub-id><pub-id pub-id-type="pmcid">PMC5000547</pub-id></element-citation></ref><ref id="B4-jcm-12-02294"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eger</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kroes</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Brinke</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Bel</surname><given-names>E.H.</given-names></name></person-group><article-title>Long-Term Therapy Response to Anti&#8211;IL-5 Biologics in Severe Asthma&#8212;A Real-Life Evaluation</article-title><source>J. Allergy Clin. Immunol. Pract.</source><year>2021</year><volume>9</volume><fpage>1194</fpage><lpage>1200</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2020.10.010</pub-id><pub-id pub-id-type="pmid">33069885</pub-id></element-citation></ref><ref id="B5-jcm-12-02294"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menzies-Gow</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>McBrien</surname><given-names>C.</given-names></name><name name-style="western"><surname>Unni</surname><given-names>B.</given-names></name><name name-style="western"><surname>Porsbjerg</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Al-Ahmad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ambrose</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Assing</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>von B&#252;low</surname><given-names>A.</given-names></name><name name-style="western"><surname>Busby</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cosio</surname><given-names>B.G.</given-names></name><etal/></person-group><article-title>Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study</article-title><source>J. Asthma Allergy</source><year>2022</year><volume>15</volume><fpage>63</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.2147/JAA.S328653</pub-id><pub-id pub-id-type="pmid">35046670</pub-id><pub-id pub-id-type="pmcid">PMC8763264</pub-id></element-citation></ref><ref id="B6-jcm-12-02294"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olivieri</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tinazzi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Caminati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lunardi</surname><given-names>C.</given-names></name></person-group><article-title>Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders</article-title><source>Immunol. Allergy Clin. North Am.</source><year>2020</year><volume>40</volume><fpage>649</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1016/j.iac.2020.07.001</pub-id><pub-id pub-id-type="pmid">33012326</pub-id></element-citation></ref><ref id="B7-jcm-12-02294"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rose</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Hrncir</surname><given-names>D.E.</given-names></name></person-group><article-title>Primary eosinophilic lung diseases</article-title><source>Allergy Asthma Proc.</source><year>2013</year><volume>34</volume><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.2500/aap.2013.34.3628</pub-id><pub-id pub-id-type="pmid">23406932</pub-id></element-citation></ref><ref id="B8-jcm-12-02294"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jennette</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Falk</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Bacon</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Basu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cid</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Ferrario</surname><given-names>F.</given-names></name><name name-style="western"><surname>Flores-Suarez</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Guillevin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hagen</surname><given-names>E.C.</given-names></name><etal/></person-group><article-title>2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides</article-title><source>Arthritis Rheum.</source><year>2013</year><volume>17</volume><fpage>603</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1002/art.37715</pub-id><pub-id pub-id-type="pmid">23045170</pub-id></element-citation></ref><ref id="B9-jcm-12-02294"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villanueva</surname><given-names>K.L.V.</given-names></name><name name-style="western"><surname>Espinoza</surname><given-names>L.R.</given-names></name></person-group><article-title>Eosinophilic Vasculitis</article-title><source>Curr. Rheumatol. Rep.</source><year>2020</year><volume>22</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.1007/s11926-020-0881-2</pub-id><pub-id pub-id-type="pmid">31927633</pub-id></element-citation></ref><ref id="B10-jcm-12-02294"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khoury</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grayson</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Klion</surname><given-names>A.D.</given-names></name></person-group><article-title>Eosinophils in vasculitis: Characteristics and roles in pathogenesis</article-title><source>Nat. Rev. Rheumatol.</source><year>2014</year><volume>10</volume><fpage>474</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2014.98</pub-id><pub-id pub-id-type="pmid">25003763</pub-id><pub-id pub-id-type="pmcid">PMC4849122</pub-id></element-citation></ref><ref id="B11-jcm-12-02294"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masi</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Hunder</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Lie</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Michel</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Bloch</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Arend</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Do</surname><given-names>L.H.C.</given-names></name><name name-style="western"><surname>Edworthy</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Fauci</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Leavitt</surname><given-names>R.Y.</given-names></name><etal/></person-group><article-title>The American College of Rheumatology 1990 criteria for the classification of churg-strauss syndrome (allergic granulomatosis and angiitis)</article-title><source>Arthritis Rheum.</source><year>2010</year><volume>33</volume><fpage>1094</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1002/art.1780330806</pub-id><pub-id pub-id-type="pmid">2202307</pub-id></element-citation></ref><ref id="B12-jcm-12-02294"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dubey</surname><given-names>S.</given-names></name></person-group><article-title>Eosinophilic granulomatosis with polyangiitis: A review</article-title><source>Autoimmun. Rev.</source><year>2022</year><volume>22</volume><fpage>103219</fpage><pub-id pub-id-type="doi">10.1016/j.autrev.2022.103219</pub-id><pub-id pub-id-type="pmid">36283646</pub-id></element-citation></ref><ref id="B13-jcm-12-02294"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sehgal</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Dhooria</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>A.N.</given-names></name></person-group><article-title>Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis</article-title><source>Expert Rev. Respir. Med.</source><year>2016</year><volume>10</volume><fpage>1317</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1080/17476348.2016.1249853</pub-id><pub-id pub-id-type="pmid">27744712</pub-id></element-citation></ref><ref id="B14-jcm-12-02294"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Greenberger</surname><given-names>P.A.</given-names></name></person-group><article-title>Allergic bronchopulmonary aspergillosis</article-title><source>Allergy Asthma Proc.</source><year>2019</year><volume>40</volume><fpage>421</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.2500/aap.2019.40.4262</pub-id><pub-id pub-id-type="pmid">31690385</pub-id></element-citation></ref><ref id="B15-jcm-12-02294"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suda</surname><given-names>T.</given-names></name></person-group><article-title>Eosinophilic pneumonia: A review of the previous literature, causes, diagnosis, and management</article-title><source>Allergol. Int.</source><year>2019</year><volume>68</volume><fpage>413</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1016/j.alit.2019.05.006</pub-id><pub-id pub-id-type="pmid">31253537</pub-id></element-citation></ref><ref id="B16-jcm-12-02294"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogbogu</surname><given-names>P.U.</given-names></name><name name-style="western"><surname>Bochner</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Butterfield</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Gleich</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Huss-Marp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Leiferman</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Nutman</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Pfab</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ring</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy</article-title><source>J. Allergy Clin. Immunol.</source><year>2009</year><volume>124</volume><fpage>1319</fpage><lpage>1325.e3</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2009.09.022</pub-id><pub-id pub-id-type="pmid">19910029</pub-id><pub-id pub-id-type="pmcid">PMC2829669</pub-id></element-citation></ref><ref id="B17-jcm-12-02294"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dulohery</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>J.H.</given-names></name></person-group><article-title>Lung involvement in hypereosinophilic syndromes</article-title><source>Respir. Med.</source><year>2011</year><volume>105</volume><fpage>114</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2010.09.011</pub-id><pub-id pub-id-type="pmid">21036585</pub-id></element-citation></ref><ref id="B18-jcm-12-02294"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shomali</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gotlib</surname><given-names>J.</given-names></name></person-group><article-title>World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management</article-title><source>Am. J. Hematol.</source><year>2019</year><volume>94</volume><fpage>1149</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1002/ajh.25617</pub-id><pub-id pub-id-type="pmid">31423623</pub-id></element-citation></ref><ref id="B19-jcm-12-02294"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Piggott</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Kent</surname><given-names>B.D.</given-names></name></person-group><article-title>Differential diagnosis of pulmonary eosinophilia</article-title><source>Eosinophilic Lung Diseases</source><publisher-name>European Respiratory Society</publisher-name><publisher-loc>Sheffield, UK</publisher-loc><year>2022</year><fpage>19</fpage><lpage>36</lpage></element-citation></ref><ref id="B20-jcm-12-02294"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rytil&#228;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Metso</surname><given-names>T.</given-names></name><name name-style="western"><surname>Heikkinen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saarelainen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Helenius</surname><given-names>I.</given-names></name><name name-style="western"><surname>Haahtela</surname><given-names>T.</given-names></name></person-group><article-title>Airway inflammation in patients with symptoms suggesting asthma but with normal lung function</article-title><source>Eur. Respir. J.</source><year>2000</year><volume>16</volume><fpage>824</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1183/09031936.00.16582400</pub-id><pub-id pub-id-type="pmid">11153578</pub-id></element-citation></ref><ref id="B21-jcm-12-02294"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>S.-W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Hwangbo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C.-S.</given-names></name></person-group><article-title>Development of Chronic Airway Obstruction in Patients with Eosinophilic Bronchitis: A Prospective Follow-Up Study</article-title><source>Chest</source><year>2004</year><volume>125</volume><fpage>1998</fpage><lpage>2004</lpage><pub-id pub-id-type="doi">10.1378/chest.125.6.1998</pub-id><pub-id pub-id-type="pmid">15189914</pub-id></element-citation></ref><ref id="B22-jcm-12-02294"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poletti</surname><given-names>V.</given-names></name></person-group><article-title>Eosinophilic bronchiolitis: Is it a new syndrome?</article-title><source>Eur. Respir. J.</source><year>2013</year><volume>41</volume><fpage>1012</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1183/09031936.00041813</pub-id><pub-id pub-id-type="pmid">23633610</pub-id></element-citation></ref><ref id="B23-jcm-12-02294"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silverman</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Sandhaus</surname><given-names>R.A.</given-names></name></person-group><article-title>Alpha<sub>1</sub>-Antitrypsin Deficiency</article-title><source>New Engl. J. Med.</source><year>2009</year><volume>360</volume><fpage>2749</fpage><lpage>2757</lpage><pub-id pub-id-type="doi">10.1056/NEJMcp0900449</pub-id><pub-id pub-id-type="pmid">19553648</pub-id></element-citation></ref><ref id="B24-jcm-12-02294"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Thoracic Society</collab><collab>European Respiratory</collab></person-group><article-title>American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2003</year><volume>168</volume><fpage>818</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1164/rccm.168.7.818</pub-id><pub-id pub-id-type="pmid">14522813</pub-id></element-citation></ref><ref id="B25-jcm-12-02294"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veith</surname><given-names>M.</given-names></name><name name-style="western"><surname>T&#252;ffers</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peychev</surname><given-names>E.</given-names></name><name name-style="western"><surname>Klemmer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kotke</surname><given-names>V.</given-names></name><name name-style="western"><surname>Janciauskiene</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wilhelm</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bals</surname><given-names>R.</given-names></name><name name-style="western"><surname>Koczulla</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Vogelmeier</surname><given-names>C.F.</given-names></name><etal/></person-group><article-title>The Distribution of Alpha-1 Antitrypsin Genotypes Between Patients with COPD/Emphysema, Asthma and Bronchiectasis</article-title><source>Int. J. Chronic Obstr. Pulm. Dis.</source><year>2020</year><volume>15</volume><fpage>2827</fpage><lpage>2836</lpage><pub-id pub-id-type="doi">10.2147/COPD.S271810</pub-id><pub-id pub-id-type="pmid">33192056</pub-id><pub-id pub-id-type="pmcid">PMC7654539</pub-id></element-citation></ref><ref id="B26-jcm-12-02294"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutchison</surname><given-names>D.</given-names></name></person-group><article-title>&#945;1-Antitrypsin deficiency in Europe: Geographical distribution of Pi types S and Z</article-title><source>Respir. Med.</source><year>1998</year><volume>92</volume><fpage>367</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/S0954-6111(98)90278-5</pub-id><pub-id pub-id-type="pmid">9692092</pub-id></element-citation></ref><ref id="B27-jcm-12-02294"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sveger</surname><given-names>T.</given-names></name></person-group><article-title>Liver Disease in Alpha<sub>1</sub>-Antitrypsin Deficiency Detected by Screening of 200,000 Infants</article-title><source>N. Engl. J. Med.</source><year>1976</year><volume>294</volume><fpage>1316</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1056/NEJM197606102942404</pub-id><pub-id pub-id-type="pmid">1083485</pub-id></element-citation></ref><ref id="B28-jcm-12-02294"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greulich</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hohmann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Grebe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Janciauskiene</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koczulla</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Vogelmeier</surname><given-names>C.F.</given-names></name></person-group><article-title>The prevalence of diagnosed &#945;<sub>1</sub>-antitrypsin deficiency and its comorbidities: Results from a large population-based database</article-title><source>Eur. Respir. J.</source><year>2017</year><volume>49</volume><fpage>1600154</fpage><pub-id pub-id-type="doi">10.1183/13993003.00154-2016</pub-id><pub-id pub-id-type="pmid">27824593</pub-id></element-citation></ref><ref id="B29-jcm-12-02294"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siri</surname><given-names>D.</given-names></name><name name-style="western"><surname>Farah</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hogarth</surname><given-names>D.K.</given-names></name></person-group><article-title>Distinguishing alpha1-antitrypsin deficiency from asthma</article-title><source>Ann. Allergy, Asthma Immunol.</source><year>2013</year><volume>111</volume><fpage>458</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1016/j.anai.2013.09.019</pub-id><pub-id pub-id-type="pmid">24267358</pub-id></element-citation></ref><ref id="B30-jcm-12-02294"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campos</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Alazemi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wanner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sandhaus</surname><given-names>R.A.</given-names></name></person-group><article-title>Effects of a Disease Management Program in Individuals with Alpha-1 Antitrypsin Deficiency</article-title><source>COPD J. Chronic Obstr. Pulm. Dis.</source><year>2009</year><volume>6</volume><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1080/15412550802607410</pub-id><pub-id pub-id-type="pmid">19229706</pub-id></element-citation></ref><ref id="B31-jcm-12-02294"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eden</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mehlman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Khouli</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nejat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grieco</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Turino</surname><given-names>G.M.</given-names></name></person-group><article-title>Atopy, Asthma, and Emphysema in Patients with Severe &#945; -1-Antitrypysin Deficiency</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>1997</year><volume>156</volume><fpage>68</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.156.1.9508014</pub-id><pub-id pub-id-type="pmid">9230728</pub-id></element-citation></ref><ref id="B32-jcm-12-02294"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eden</surname><given-names>E.</given-names></name><name name-style="western"><surname>Holbrook</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Brantly</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Turino</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Wise</surname><given-names>R.A.</given-names></name></person-group><article-title>Prevalence of Alpha-1 Antitrypsin Deficiency in Poorly Controlled Asthma&#8212;Results from the ALA-ACRC Low-Dose Theophylline Trial</article-title><source>J. Asthma</source><year>2007</year><volume>44</volume><fpage>605</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1080/02770900701540028</pub-id><pub-id pub-id-type="pmid">17943569</pub-id></element-citation></ref><ref id="B33-jcm-12-02294"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vianello</surname><given-names>A.</given-names></name><name name-style="western"><surname>Caminati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Senna</surname><given-names>G.</given-names></name><name name-style="western"><surname>Arcolaci</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chieco-Bianchi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ferrarotti</surname><given-names>I.</given-names></name><name name-style="western"><surname>Guarnieri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Molena</surname><given-names>B.</given-names></name><name name-style="western"><surname>Crisafulli</surname><given-names>E.</given-names></name></person-group><article-title>Effect of &#945;1 antitrypsin deficiency on lung volume decline in severe asthmatic patients undergoing biologic therapy</article-title><source>J. Allergy Clin. Immunol. Pract.</source><year>2021</year><volume>9</volume><fpage>1414</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2020.12.061</pub-id><pub-id pub-id-type="pmid">33440256</pub-id></element-citation></ref><ref id="B34-jcm-12-02294"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su&#225;rez-Lorenzo</surname><given-names>I.</given-names></name><name name-style="western"><surname>De Castro</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Cruz-Niesvaara</surname><given-names>D.</given-names></name><name name-style="western"><surname>Herrera-Ramos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Gallego</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carrillo-Diaz</surname><given-names>T.</given-names></name></person-group><article-title>Alpha 1 antitrypsin distribution in an allergic asthmatic population sensitized to house dust mites</article-title><source>Clin. Transl. Allergy</source><year>2018</year><volume>8</volume><fpage>44</fpage><pub-id pub-id-type="doi">10.1186/s13601-018-0231-x</pub-id><pub-id pub-id-type="pmid">30410723</pub-id><pub-id pub-id-type="pmcid">PMC6214172</pub-id></element-citation></ref><ref id="B35-jcm-12-02294"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Veen</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Brinke</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>van der Linden</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rabe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bel</surname><given-names>E.</given-names></name></person-group><article-title>Deficient alpha-1-antitrypsin phenotypes and persistent airflow limitation in severe asthma</article-title><source>Respir. Med.</source><year>2006</year><volume>100</volume><fpage>1534</fpage><lpage>1539</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2006.01.009</pub-id><pub-id pub-id-type="pmid">16476537</pub-id></element-citation></ref><ref id="B36-jcm-12-02294"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Needham</surname><given-names>M.</given-names></name></person-group><article-title>1-Antitrypsin deficiency 3: Clinical manifestations and natural history</article-title><source>Thorax</source><year>2004</year><volume>59</volume><fpage>441</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1136/thx.2003.006510</pub-id><pub-id pub-id-type="pmid">15115878</pub-id><pub-id pub-id-type="pmcid">PMC1746985</pub-id></element-citation></ref><ref id="B37-jcm-12-02294"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eden</surname><given-names>E.</given-names></name></person-group><article-title>Asthma and COPD in Alpha-1 Antitrypsin Deficiency. Evidence for the Dutch Hypothesis</article-title><source>COPD J. Chronic Obstr. Pulm. Dis.</source><year>2010</year><volume>7</volume><fpage>366</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.3109/15412555.2010.510159</pub-id><pub-id pub-id-type="pmid">20854052</pub-id></element-citation></ref><ref id="B38-jcm-12-02294"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cazzola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stolz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rogliani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Matera</surname><given-names>M.G.</given-names></name></person-group><article-title>&#945;<sub>1</sub>-Antitrypsin deficiency and chronic respiratory disorders</article-title><source>Eur. Respir. Rev.</source><year>2020</year><volume>29</volume><fpage>190073</fpage><pub-id pub-id-type="doi">10.1183/16000617.0073-2019</pub-id><pub-id pub-id-type="pmid">32051168</pub-id><pub-id pub-id-type="pmcid">PMC9488707</pub-id></element-citation></ref><ref id="B39-jcm-12-02294"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vignola</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Bonanno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mirabella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Riccobono</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mirabella</surname><given-names>F.</given-names></name><name name-style="western"><surname>Profita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bellia</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bousquet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bonsignore</surname><given-names>G.</given-names></name></person-group><article-title>Increased Levels of Elastase and &#945;<sub>1</sub>-Antitrypsin in Sputum of Asthmatic Patients</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>1998</year><volume>157</volume><fpage>505</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.157.2.9703070</pub-id><pub-id pub-id-type="pmid">9476865</pub-id></element-citation></ref><ref id="B40-jcm-12-02294"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Craig</surname><given-names>T.J.</given-names></name></person-group><article-title>Suspecting and Testing for Alpha-1 Antitrypsin Deficiency&#8212;An Allergist&#8217;s and/or Immunologist&#8217;s Perspective</article-title><source>J. Allergy Clin. Immunol. Pract.</source><year>2015</year><volume>3</volume><fpage>506</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2015.04.005</pub-id><pub-id pub-id-type="pmid">26032475</pub-id></element-citation></ref><ref id="B41-jcm-12-02294"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dirksen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Piitulainen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Parr</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wencker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shaker</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Stockley</surname><given-names>R.A.</given-names></name></person-group><article-title>Exploring the role of CT densitometry: A randomised study of augmentation therapy in 1-antitrypsin deficiency</article-title><source>Eur. Respir. J.</source><year>2009</year><volume>33</volume><fpage>1345</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.1183/09031936.00159408</pub-id><pub-id pub-id-type="pmid">19196813</pub-id></element-citation></ref><ref id="B42-jcm-12-02294"><label>42.</label><element-citation publication-type="webpage"><article-title>GINA ASTHMA</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.ginasthma.org" ext-link-type="uri">www.ginasthma.org</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-01">(accessed on 1 December 2022)</date-in-citation></element-citation></ref><ref id="B43-jcm-12-02294"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eden</surname><given-names>E.</given-names></name><name name-style="western"><surname>Strange</surname><given-names>C.</given-names></name><name name-style="western"><surname>Holladay</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name></person-group><article-title>Asthma and allergy in alpha-1 antitrypsin deficiency</article-title><source>Respir. Med.</source><year>2006</year><volume>100</volume><fpage>1384</fpage><lpage>1391</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2005.11.017</pub-id><pub-id pub-id-type="pmid">16403617</pub-id></element-citation></ref><ref id="B44-jcm-12-02294"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiotiu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salvator</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jaussaud</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jankowski</surname><given-names>R.</given-names></name><name name-style="western"><surname>Couderc</surname><given-names>L.-J.</given-names></name><name name-style="western"><surname>Catherinot</surname><given-names>E.</given-names></name><name name-style="western"><surname>Devillier</surname><given-names>P.</given-names></name></person-group><article-title>Efficacy of immunoglobulin replacement therapy and azithromycin in severe asthma with antibody deficiency</article-title><source>Allergol. Int.</source><year>2020</year><volume>69</volume><fpage>215</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.alit.2019.10.011</pub-id><pub-id pub-id-type="pmid">31812484</pub-id></element-citation></ref><ref id="B45-jcm-12-02294"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urm</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Fenta</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Hagan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Juhn</surname><given-names>Y.J.</given-names></name></person-group><article-title>Asthma and Risk of Selective IgA Deficiency or Common Variable Immunodeficiency: A Population-Based Case-Control Study</article-title><source>Mayo Clin. Proc.</source><year>2013</year><volume>88</volume><fpage>813</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2013.05.021</pub-id><pub-id pub-id-type="pmid">23910409</pub-id><pub-id pub-id-type="pmcid">PMC3753684</pub-id></element-citation></ref><ref id="B46-jcm-12-02294"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Schulman</surname><given-names>E.S.</given-names></name></person-group><article-title>Primary immune deficiency diseases as unrecognized causes of chronic respiratory disease</article-title><source>Respir. Med.</source><year>2017</year><volume>132</volume><fpage>181</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2017.10.016</pub-id><pub-id pub-id-type="pmid">29229095</pub-id></element-citation></ref><ref id="B47-jcm-12-02294"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fardet</surname><given-names>L.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nazareth</surname><given-names>I.</given-names></name></person-group><article-title>Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study</article-title><source>PLoS Med.</source><year>2016</year><volume>13</volume><elocation-id>e1002024</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1002024</pub-id><pub-id pub-id-type="pmid">27218256</pub-id><pub-id pub-id-type="pmcid">PMC4878789</pub-id></element-citation></ref><ref id="B48-jcm-12-02294"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Ban</surname><given-names>G.-Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.-C.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>C.-G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.-S.</given-names></name></person-group><article-title>Association between primary immunodeficiency and asthma exacerbation in adult asthmatics</article-title><source>Korean J. Intern. Med.</source><year>2020</year><volume>35</volume><fpage>449</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.3904/kjim.2018.413</pub-id><pub-id pub-id-type="pmid">31185709</pub-id><pub-id pub-id-type="pmcid">PMC7060996</pub-id></element-citation></ref><ref id="B49-jcm-12-02294"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y.-M.</given-names></name><name name-style="western"><surname>Ban</surname><given-names>G.-Y.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>Y.-S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.-K.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>K.-S.</given-names></name><etal/></person-group><article-title>Effects of Immunoglobulin Replacement on Asthma Exacerbation in Adult Asthmatics with IgG Subclass Deficiency</article-title><source>Allergy, Asthma Immunol. Res.</source><year>2017</year><volume>9</volume><fpage>526</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.4168/aair.2017.9.6.526</pub-id><pub-id pub-id-type="pmid">28913992</pub-id><pub-id pub-id-type="pmcid">PMC5603481</pub-id></element-citation></ref><ref id="B50-jcm-12-02294"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dupin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marchand-Adam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Favelle</surname><given-names>O.</given-names></name><name name-style="western"><surname>Costes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gatault</surname><given-names>P.</given-names></name><name name-style="western"><surname>Diot</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grammatico-Guillon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guilleminault</surname><given-names>L.</given-names></name></person-group><article-title>Asthma and Hypogammaglobulinemia: An Asthma Phenotype with Low Type 2 Inflammation</article-title><source>J. Clin. Immunol.</source><year>2016</year><volume>36</volume><fpage>810</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1007/s10875-016-0335-9</pub-id><pub-id pub-id-type="pmid">27714565</pub-id></element-citation></ref><ref id="B51-jcm-12-02294"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kishiyama</surname><given-names>J.</given-names></name><name name-style="western"><surname>Valacer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rundlesb</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sperber</surname><given-names>K.</given-names></name><name name-style="western"><surname>Richmond</surname><given-names>G.</given-names></name><name name-style="western"><surname>Abramson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Glovsky</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stiehm</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stocks</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of High-Dose Intravenous Immunoglobulin for Oral Corticosteroid-Dependent Asthma</article-title><source>Clin. Immunol.</source><year>1999</year><volume>91</volume><fpage>126</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1006/clim.1999.4714</pub-id><pub-id pub-id-type="pmid">10227804</pub-id></element-citation></ref><ref id="B52-jcm-12-02294"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Franceschi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brugnara</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rouyer-Fessard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jouault</surname><given-names>H.</given-names></name><name name-style="western"><surname>Beuzard</surname><given-names>Y.</given-names></name></person-group><article-title>Formation of dense erythrocytes in SAD mice exposed to chronic hypoxia: Evaluation of different therapeutic regimens and of a combination of oral clotrimazole and magnesium therapies</article-title><source>Blood</source><year>1999</year><volume>94</volume><fpage>4307</fpage><lpage>4313</lpage><pub-id pub-id-type="doi">10.1182/blood.V94.12.4307</pub-id><pub-id pub-id-type="pmid">10590075</pub-id></element-citation></ref><ref id="B53-jcm-12-02294"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Franceschi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bertoldi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Pantaleo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferru</surname><given-names>E.</given-names></name><name name-style="western"><surname>Turrini</surname><given-names>F.</given-names></name></person-group><article-title>Oxidative Stress and&#946;-Thalassemic Erythroid Cells behind the Molecular Defect</article-title><source>Oxidative Med. Cell. Longev.</source><year>2013</year><volume>2013</volume><fpage>985210</fpage><pub-id pub-id-type="doi">10.1155/2013/985210</pub-id><pub-id pub-id-type="pmcid">PMC3800594</pub-id><pub-id pub-id-type="pmid">24205432</pub-id></element-citation></ref><ref id="B54-jcm-12-02294"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalish</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Matte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Andolfo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Iolascon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ghigo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cimino</surname><given-names>J.</given-names></name><name name-style="western"><surname>Siciliano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>E.</given-names></name><name name-style="western"><surname>Federti</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Dietary &#969;-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease</article-title><source>Haematologica</source><year>2015</year><volume>100</volume><fpage>870</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.3324/haematol.2015.124586</pub-id><pub-id pub-id-type="pmid">25934765</pub-id><pub-id pub-id-type="pmcid">PMC4486221</pub-id></element-citation></ref><ref id="B55-jcm-12-02294"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Recchiuti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Federti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Koehl</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mintz</surname><given-names>T.</given-names></name><name name-style="western"><surname>El Nemer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tharaux</surname><given-names>P.-L.</given-names></name><name name-style="western"><surname>Brousse</surname><given-names>V.</given-names></name><name name-style="western"><surname>Andolfo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lamolinara</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Resolution of sickle cell disease&#8211;associated inflammation and tissue damage with 17R-resolvin D1</article-title><source>Blood</source><year>2019</year><volume>133</volume><fpage>252</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-07-865378</pub-id><pub-id pub-id-type="pmid">30404812</pub-id><pub-id pub-id-type="pmcid">PMC6337877</pub-id></element-citation></ref><ref id="B56-jcm-12-02294"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cappellini</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Iolascon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Enrica</surname><given-names>F.</given-names></name><name name-style="western"><surname>De Franceschi</surname><given-names>L.</given-names></name></person-group><article-title>Emerging drugs in randomized controlled trials for sickle cell disease: Are we on the brink of a new era in research and treatment?</article-title><source>Expert Opin. Investig. Drugs</source><year>2020</year><volume>29</volume><fpage>23</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1080/13543784.2020.1703947</pub-id><pub-id pub-id-type="pmid">31847604</pub-id></element-citation></ref><ref id="B57-jcm-12-02294"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franceschi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cappellini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Olivieri</surname><given-names>O.</given-names></name></person-group><article-title>Thrombosis and Sickle Cell Disease</article-title><source>Semin. Thromb. Hemost.</source><year>2011</year><volume>37</volume><fpage>226</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1055/s-0031-1273087</pub-id><pub-id pub-id-type="pmid">21455857</pub-id></element-citation></ref><ref id="B58-jcm-12-02294"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Platt</surname><given-names>O.S.</given-names></name></person-group><article-title>The Acute Chest Syndrome of Sickle Cell Disease</article-title><source>New Engl. J. Med.</source><year>2000</year><volume>342</volume><fpage>1904</fpage><lpage>1907</lpage><pub-id pub-id-type="doi">10.1056/NEJM200006223422510</pub-id><pub-id pub-id-type="pmid">10861328</pub-id></element-citation></ref><ref id="B59-jcm-12-02294"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Piel</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Gaston</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Ohene-Frempong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Krishnamurti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Panepinto</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Weatherall</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>F.F.</given-names></name><etal/></person-group><article-title>Sickle cell disease</article-title><source>Nat. Rev. Dis. Prim.</source><year>2018</year><volume>4</volume><fpage>18010</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2018.10</pub-id><pub-id pub-id-type="pmid">29542687</pub-id></element-citation></ref><ref id="B60-jcm-12-02294"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Klings</surname><given-names>E.S.</given-names></name></person-group><article-title>Chronic Pulmonary Complications of Sickle Cell Disease</article-title><source>Chest</source><year>2016</year><volume>149</volume><fpage>1313</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2015.11.016</pub-id><pub-id pub-id-type="pmid">26836905</pub-id><pub-id pub-id-type="pmcid">PMC6026273</pub-id></element-citation></ref><ref id="B61-jcm-12-02294"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samarasinghe</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Rosch</surname><given-names>J.W.</given-names></name></person-group><article-title>Convergence of Inflammatory Pathways in Allergic Asthma and Sickle Cell Disease</article-title><source>Front. Immunol.</source><year>2020</year><volume>10</volume><fpage>3058</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.03058</pub-id><pub-id pub-id-type="pmid">32038616</pub-id><pub-id pub-id-type="pmcid">PMC6992560</pub-id></element-citation></ref><ref id="B62-jcm-12-02294"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Klings</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Strunk</surname><given-names>R.C.</given-names></name></person-group><article-title>Sickle cell disease: Wheeze or asthma?</article-title><source>Asthma Res. Pract.</source><year>2015</year><volume>1</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/s40733-015-0014-2</pub-id><pub-id pub-id-type="pmid">27965767</pub-id><pub-id pub-id-type="pmcid">PMC5142438</pub-id></element-citation></ref><ref id="B63-jcm-12-02294"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arigliani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A.</given-names></name></person-group><article-title>Management of chronic respiratory complications in children and adolescents with sickle cell disease</article-title><source>Eur. Respir. Rev.</source><year>2020</year><volume>29</volume><fpage>200054</fpage><pub-id pub-id-type="doi">10.1183/16000617.0054-2020</pub-id><pub-id pub-id-type="pmid">32817114</pub-id><pub-id pub-id-type="pmcid">PMC9488589</pub-id></element-citation></ref><ref id="B64-jcm-12-02294"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strunk</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Rodeghier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kirkham</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Warner</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Stocks</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kirkby</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>C.L.</given-names></name><etal/></person-group><article-title>Wheezing Symptoms and Parental Asthma Are Associated with a Physician Diagnosis of Asthma in Children with Sickle Cell Anemia</article-title><source>J. Pediatr.</source><year>2014</year><volume>164</volume><fpage>821</fpage><lpage>826.e1</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2013.11.034</pub-id><pub-id pub-id-type="pmid">24388323</pub-id><pub-id pub-id-type="pmcid">PMC3962704</pub-id></element-citation></ref><ref id="B65-jcm-12-02294"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyd</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Macklin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Strunk</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>DeBaun</surname><given-names>M.R.</given-names></name></person-group><article-title>Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia</article-title><source>Blood</source><year>2006</year><volume>108</volume><fpage>2923</fpage><lpage>2927</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-01-011072</pub-id><pub-id pub-id-type="pmid">16690969</pub-id><pub-id pub-id-type="pmcid">PMC1892235</pub-id></element-citation></ref><ref id="B66-jcm-12-02294"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vichinsky</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>A Styles</surname><given-names>L.</given-names></name><name name-style="western"><surname>Colangelo</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>O.</given-names></name><name name-style="western"><surname>Nickerson</surname><given-names>B.</given-names></name></person-group><article-title>Acute chest syndrome in sickle cell disease: Clinical presentation and course: Cooperative Study of Sickle Cell Disease</article-title><source>Blood</source><year>1997</year><volume>89</volume><fpage>1787</fpage><lpage>1792</lpage><pub-id pub-id-type="doi">10.1182/blood.V89.5.1787</pub-id><pub-id pub-id-type="pmid">9057664</pub-id></element-citation></ref><ref id="B67-jcm-12-02294"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vichinsky</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Neumayr</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Earles</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lennette</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nickerson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Orringer</surname><given-names>E.</given-names></name><name name-style="western"><surname>McKie</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bellevue</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease</article-title><source>N. Engl. J. Med.</source><year>2000</year><volume>342</volume><fpage>1855</fpage><lpage>1865</lpage><pub-id pub-id-type="doi">10.1056/NEJM200006223422502</pub-id><pub-id pub-id-type="pmid">10861320</pub-id></element-citation></ref><ref id="B68-jcm-12-02294"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Madadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blinder</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>DeBaun</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Strunk</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Field</surname><given-names>J.J.</given-names></name></person-group><article-title>Recurrent, severe wheezing is associated with morbidity and mortality in adults with sickle cell disease</article-title><source>Am. J. Hematol.</source><year>2011</year><volume>86</volume><fpage>756</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1002/ajh.22098</pub-id><pub-id pub-id-type="pmid">21809369</pub-id><pub-id pub-id-type="pmcid">PMC4103016</pub-id></element-citation></ref><ref id="B69-jcm-12-02294"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glassberg</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wisnivesky</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>R.</given-names></name><name name-style="western"><surname>DeBaun</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>L.D.</given-names></name></person-group><article-title>Wheezing and asthma are independent risk factors for increased sickle cell disease morbidity</article-title><source>Br. J. Haematol.</source><year>2012</year><volume>159</volume><fpage>472</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1111/bjh.12049</pub-id><pub-id pub-id-type="pmid">22966893</pub-id><pub-id pub-id-type="pmcid">PMC3758903</pub-id></element-citation></ref><ref id="B70-jcm-12-02294"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Klings</surname><given-names>E.S.</given-names></name></person-group><article-title>Commentary: Heterogeneity of respiratory disease in children and young adults with sickle cell disease</article-title><source>Thorax</source><year>2018</year><volume>73</volume><page-range>503&#8211;503</page-range><pub-id pub-id-type="doi">10.1136/thoraxjnl-2017-211370</pub-id><pub-id pub-id-type="pmid">29353255</pub-id></element-citation></ref><ref id="B71-jcm-12-02294"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bokov</surname><given-names>P.</given-names></name><name name-style="western"><surname>El Jurdi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Denjoy</surname><given-names>I.</given-names></name><name name-style="western"><surname>Peiffer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Medjahdi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Holvoet</surname><given-names>L.</given-names></name><name name-style="western"><surname>Benkerrou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Delclaux</surname><given-names>C.</given-names></name></person-group><article-title>Salbutamol Worsens the Autonomic Nervous System Dysfunction of Children with Sickle Cell Disease</article-title><source>Front. Physiol.</source><year>2020</year><volume>11</volume><fpage>31</fpage><pub-id pub-id-type="doi">10.3389/fphys.2020.00031</pub-id><pub-id pub-id-type="pmid">32174840</pub-id><pub-id pub-id-type="pmcid">PMC7054439</pub-id></element-citation></ref><ref id="B72-jcm-12-02294"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>A.M.</given-names></name></person-group><article-title>The role of the endothelium in asthma and chronic obstructive pulmonary disease (COPD)</article-title><source>Respir. Res.</source><year>2017</year><volume>18</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.1186/s12931-017-0505-1</pub-id><pub-id pub-id-type="pmid">28100233</pub-id><pub-id pub-id-type="pmcid">PMC5241996</pub-id></element-citation></ref><ref id="B73-jcm-12-02294"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brandow</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Creary</surname><given-names>S.</given-names></name><name name-style="western"><surname>Edwards-Elliott</surname><given-names>R.</given-names></name><name name-style="western"><surname>Glassberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hurley</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Kutlar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seisa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stinson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Strouse</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>American Society of Hematology 2020 guidelines for sickle cell disease: Management of acute and chronic pain</article-title><source>Blood Adv.</source><year>2020</year><volume>4</volume><fpage>2656</fpage><lpage>2701</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2020001851</pub-id><pub-id pub-id-type="pmcid">PMC7322963</pub-id><pub-id pub-id-type="pmid">32559294</pub-id></element-citation></ref><ref id="B74-jcm-12-02294"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pervaiz</surname><given-names>A.</given-names></name><name name-style="western"><surname>El-Baba</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dhillon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Daoud</surname><given-names>A.</given-names></name><name name-style="western"><surname>Soubani</surname><given-names>A.</given-names></name></person-group><article-title>Pulmonary Complications of Sickle Cell Disease: A Narrative Clinical Review</article-title><source>Adv. Respir. Med.</source><year>2021</year><volume>89</volume><fpage>173</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.5603/ARM.a2021.0011</pub-id><pub-id pub-id-type="pmid">33881157</pub-id></element-citation></ref><ref id="B75-jcm-12-02294"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>T.-P.</given-names></name><name name-style="western"><surname>Chiam</surname><given-names>P.-C.</given-names></name><name name-style="western"><surname>Kua</surname><given-names>E.-H.</given-names></name></person-group><article-title>Mental disorders and asthma in the elderly: A population-based study</article-title><source>Int. J. Geriatr. Psychiatry</source><year>2006</year><volume>22</volume><fpage>668</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1002/gps.1728</pub-id><pub-id pub-id-type="pmid">17154223</pub-id></element-citation></ref><ref id="B76-jcm-12-02294"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eriksson</surname><given-names>U.K.</given-names></name><name name-style="western"><surname>Gatz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dickman</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Fratiglioni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>N.L.</given-names></name></person-group><article-title>Asthma, Eczema, Rhinitis and the Risk for Dementia</article-title><source>Dement. Geriatr. Cogn. Disord.</source><year>2008</year><volume>25</volume><fpage>148</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1159/000112729</pub-id><pub-id pub-id-type="pmid">18097143</pub-id></element-citation></ref><ref id="B77-jcm-12-02294"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rusanen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ngandu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Laatikainen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tuomilehto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Soininen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kivipelto</surname><given-names>M.</given-names></name></person-group><article-title>Chronic Obstructive Pulmonary Disease and Asthma and the Risk of Mild Cognitive Impairment and Dementia: A Population Based CAIDE Study</article-title><source>Curr. Alzheimer Res.</source><year>2013</year><volume>10</volume><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.2174/1567205011310050011</pub-id><pub-id pub-id-type="pmid">23566344</pub-id></element-citation></ref><ref id="B78-jcm-12-02294"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M.-H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.-T.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>C.-F.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W.-C.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>W.-H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.-J.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>T.-L.</given-names></name><name name-style="western"><surname>Su</surname><given-names>T.-P.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y.-M.</given-names></name></person-group><article-title>Risk of Dementia Among Patients with Asthma: A Nationwide Longitudinal Study</article-title><source>J. Am. Med. Dir. Assoc.</source><year>2014</year><volume>15</volume><fpage>763</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1016/j.jamda.2014.06.003</pub-id><pub-id pub-id-type="pmid">25037169</pub-id></element-citation></ref><ref id="B79-jcm-12-02294"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lutsey</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mirabelli</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Lakshminarayan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Vossel</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Gottesman</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Mosley</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>A.</given-names></name></person-group><article-title>Impaired Lung Function, Lung Disease, and Risk of Incident Dementia</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2019</year><volume>199</volume><fpage>1385</fpage><lpage>1396</lpage><pub-id pub-id-type="doi">10.1164/rccm.201807-1220OC</pub-id><pub-id pub-id-type="pmid">30433810</pub-id><pub-id pub-id-type="pmcid">PMC6543713</pub-id></element-citation></ref><ref id="B80-jcm-12-02294"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B.-R.</given-names></name><name name-style="western"><surname>Su</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>W.-C.</given-names></name><name name-style="western"><surname>Muo</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Hsia</surname><given-names>T.-C.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>C.-H.</given-names></name></person-group><article-title>Adult asthma increases dementia risk: A nationwide cohort study</article-title><source>J. Epidemiol. Community Health</source><year>2014</year><volume>69</volume><fpage>123</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1136/jech-2014-204445</pub-id><pub-id pub-id-type="pmid">25271249</pub-id></element-citation></ref><ref id="B81-jcm-12-02294"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caldera-Alvarado</surname><given-names>G.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>DeFina</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Pieper</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>E.S.</given-names></name></person-group><article-title>Relationship between asthma and cognition: The Cooper Center Longitudinal Study</article-title><source>Allergy</source><year>2013</year><volume>68</volume><fpage>545</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1111/all.12125</pub-id><pub-id pub-id-type="pmid">23409872</pub-id></element-citation></ref><ref id="B82-jcm-12-02294"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Barbone</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Beausoleil</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gerald</surname><given-names>L.</given-names></name></person-group><article-title>Is asthma associated with cognitive impairments? A meta-analytic review</article-title><source>J. Clin. Exp. Neuropsychol.</source><year>2017</year><volume>39</volume><fpage>965</fpage><lpage>978</lpage><pub-id pub-id-type="doi">10.1080/13803395.2017.1288802</pub-id><pub-id pub-id-type="pmid">28325118</pub-id></element-citation></ref><ref id="B83-jcm-12-02294"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>A Hawkins</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hastie</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Israel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Mauger</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>A Comhair</surname><given-names>S.</given-names></name><name name-style="western"><surname>Erzurum</surname><given-names>S.C.</given-names></name><etal/></person-group><article-title>Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: A cross-sectional analysis of two cohorts</article-title><source>Lancet Respir. Med.</source><year>2016</year><volume>4</volume><fpage>574</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(16)30048-0</pub-id><pub-id pub-id-type="pmid">27283230</pub-id><pub-id pub-id-type="pmcid">PMC5007068</pub-id></element-citation></ref><ref id="B84-jcm-12-02294"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuleta</surname><given-names>I.</given-names></name><name name-style="western"><surname>Skowasch</surname><given-names>D.</given-names></name><name name-style="western"><surname>Aurich</surname><given-names>F.</given-names></name><name name-style="western"><surname>Eckstein</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schueler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pizarro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schahab</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nickenig</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pingel</surname><given-names>S.</given-names></name></person-group><article-title>Asthma is associated with atherosclerotic artery changes</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0186820</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0186820</pub-id><pub-id pub-id-type="pmid">29073174</pub-id><pub-id pub-id-type="pmcid">PMC5658104</pub-id></element-citation></ref><ref id="B85-jcm-12-02294"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tattersall</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Korcarz</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>E.</given-names></name><name name-style="western"><surname>DaSilva</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Gern</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>J.H.</given-names></name></person-group><article-title>Asthma is associated with carotid arterial injury in children: The Childhood Origins of Asthma (COAST) Cohort</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0204708</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0204708</pub-id><pub-id pub-id-type="pmid">30261051</pub-id><pub-id pub-id-type="pmcid">PMC6160166</pub-id></element-citation></ref><ref id="B86-jcm-12-02294"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenkranz</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Bendlin</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Jarjour</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Esnault</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Heslegrave</surname><given-names>A.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Busse</surname><given-names>W.W.</given-names></name></person-group><article-title>Neuroimaging and biomarker evidence of neurodegeneration in asthma</article-title><source>J. Allergy Clin. Immunol.</source><year>2022</year><volume>149</volume><fpage>589</fpage><lpage>598.e6</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2021.09.010</pub-id><pub-id pub-id-type="pmid">34536414</pub-id><pub-id pub-id-type="pmcid">PMC8821112</pub-id></element-citation></ref><ref id="B87-jcm-12-02294"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenkranz</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Busse</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Sheridan</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Crisafi</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>R.J.</given-names></name></person-group><article-title>Are There Neurophenotypes for Asthma? Functional Brain Imaging of the Interaction between Emotion and Inflammation in Asthma</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e40921</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0040921</pub-id><pub-id pub-id-type="pmid">22870208</pub-id><pub-id pub-id-type="pmcid">PMC3411610</pub-id></element-citation></ref><ref id="B88-jcm-12-02294"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kroll</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Steele</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Pinkham</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Aslan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Ritz</surname><given-names>T.</given-names></name></person-group><article-title>Hippocampal metabolites in asthma and their implications for cognitive function</article-title><source>NeuroImage Clin.</source><year>2018</year><volume>19</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.nicl.2018.04.012</pub-id><pub-id pub-id-type="pmid">30035015</pub-id><pub-id pub-id-type="pmcid">PMC6051470</pub-id></element-citation></ref><ref id="B89-jcm-12-02294"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Woolston</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Frol</surname><given-names>A.B.</given-names></name></person-group><article-title>Amygdala Volume in Patients Receiving Chronic Corticosteroid Therapy</article-title><source>Biol. Psychiatry</source><year>2008</year><volume>63</volume><fpage>705</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2007.09.014</pub-id><pub-id pub-id-type="pmid">17981265</pub-id><pub-id pub-id-type="pmcid">PMC3291486</pub-id></element-citation></ref><ref id="B90-jcm-12-02294"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marschallinger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Altendorfer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rockenstein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Holztrattner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garnweidner-Raith</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pillichshammer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Leister</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hutter-Paier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Strempfl</surname><given-names>K.</given-names></name><name name-style="western"><surname>Unger</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies</article-title><source>Neurotherapeutics</source><year>2020</year><volume>17</volume><fpage>1061</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1007/s13311-020-00836-3</pub-id><pub-id pub-id-type="pmid">32072462</pub-id><pub-id pub-id-type="pmcid">PMC7609773</pub-id></element-citation></ref><ref id="B91-jcm-12-02294"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karamzad</surname><given-names>N.</given-names></name><name name-style="western"><surname>Izadi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sanaie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmadian</surname><given-names>E.</given-names></name><name name-style="western"><surname>Eftekhari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sullman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Safiri</surname><given-names>S.</given-names></name></person-group><article-title>Asthma and metabolic syndrome: A comprehensive systematic review and meta-analysis of observational studies</article-title><source>J. Cardiovasc. Thorac. Res.</source><year>2020</year><volume>12</volume><fpage>120</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.34172/jcvtr.2020.20</pub-id><pub-id pub-id-type="pmid">32626552</pub-id><pub-id pub-id-type="pmcid">PMC7321001</pub-id></element-citation></ref><ref id="B92-jcm-12-02294"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Boer</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Tramper-Stranders</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Houweling</surname><given-names>L.</given-names></name><name name-style="western"><surname>van Zelst</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Pouw</surname><given-names>N.</given-names></name><name name-style="western"><surname>Verhoeven</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Klerk</surname><given-names>B.M.B.-D.</given-names></name><name name-style="western"><surname>Veen</surname><given-names>J.C.I.</given-names></name><name name-style="western"><surname>van Rossum</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Hendriks</surname><given-names>R.W.</given-names></name><etal/></person-group><article-title>Adult but not childhood onset asthma is associated with the metabolic syndrome, independent from body mass index</article-title><source>Respir. Med.</source><year>2021</year><volume>188</volume><fpage>106603</fpage><pub-id pub-id-type="doi">10.1016/j.rmed.2021.106603</pub-id><pub-id pub-id-type="pmid">34530355</pub-id></element-citation></ref><ref id="B93-jcm-12-02294"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brumpton</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Camargo</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Romundstad</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Langhammer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mai</surname><given-names>X.-M.</given-names></name></person-group><article-title>Metabolic syndrome and incidence of asthma in adults: The HUNT study</article-title><source>Eur. Respir. J.</source><year>2013</year><volume>42</volume><fpage>1495</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1183/09031936.00046013</pub-id><pub-id pub-id-type="pmid">23845717</pub-id></element-citation></ref><ref id="B94-jcm-12-02294"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Brigham</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Keet</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Hansel</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>McCormack</surname><given-names>M.C.</given-names></name></person-group><article-title>Association Between Prediabetes/Diabetes and Asthma Exacerbations in a Claims-Based Obese Asthma Cohort</article-title><source>J. Allergy Clin. Immunol. Pract.</source><year>2019</year><volume>7</volume><fpage>1868</fpage><lpage>1873.e5</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2019.02.029</pub-id><pub-id pub-id-type="pmid">30857941</pub-id><pub-id pub-id-type="pmcid">PMC6612446</pub-id></element-citation></ref><ref id="B95-jcm-12-02294"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Forno</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Rosser</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Celed&#243;n</surname><given-names>J.C.</given-names></name></person-group><article-title>Glycated Hemoglobin A1c, Lung Function, and Hospitalizations Among Adults with Asthma</article-title><source>J. Allergy Clin. Immunol. Pract.</source><year>2020</year><volume>8</volume><fpage>3409</fpage><lpage>3415.e1</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2020.06.017</pub-id><pub-id pub-id-type="pmid">32569755</pub-id><pub-id pub-id-type="pmcid">PMC7655696</pub-id></element-citation></ref><ref id="B96-jcm-12-02294"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thuesen</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Husemoen</surname><given-names>L.L.N.</given-names></name><name name-style="western"><surname>Hersoug</surname><given-names>L.-G.</given-names></name><name name-style="western"><surname>Pisinger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Linneberg</surname><given-names>A.</given-names></name></person-group><article-title>Insulin resistance as a predictor of incident asthma-like symptoms in adults</article-title><source>Clin. Exp. Allergy</source><year>2009</year><volume>39</volume><fpage>700</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2222.2008.03197.x</pub-id><pub-id pub-id-type="pmid">19260867</pub-id></element-citation></ref><ref id="B97-jcm-12-02294"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>T.D.</given-names></name></person-group><article-title>Diabetes, insulin resistance, and asthma: A review of potential links</article-title><source>Curr. Opin. Pulm. Med.</source><year>2021</year><volume>27</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1097/MCP.0000000000000738</pub-id><pub-id pub-id-type="pmid">33002990</pub-id></element-citation></ref><ref id="B98-jcm-12-02294"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christiansen</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Schatz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Ngor</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zuraw</surname><given-names>B.</given-names></name></person-group><article-title>Hypertension and Asthma: A Comorbid Relationship</article-title><source>J. Allergy Clin. Immunol. Pract.</source><year>2016</year><volume>4</volume><fpage>76</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2015.07.009</pub-id><pub-id pub-id-type="pmid">26342745</pub-id></element-citation></ref><ref id="B99-jcm-12-02294"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madhur</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lob</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>McCann</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Iwakura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Blinder</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guzik</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>D.G.</given-names></name></person-group><article-title>Interleukin 17 Promotes Angiotensin II&#8211;Induced Hypertension and Vascular Dysfunction</article-title><source>Hypertension</source><year>2010</year><volume>55</volume><fpage>500</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.109.145094</pub-id><pub-id pub-id-type="pmid">20038749</pub-id><pub-id pub-id-type="pmcid">PMC2819301</pub-id></element-citation></ref><ref id="B100-jcm-12-02294"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chesn&#233;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Braza</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chadeuf</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mahay</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cheminant</surname><given-names>M.-A.</given-names></name><name name-style="western"><surname>Loy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brouard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sauzeau</surname><given-names>V.</given-names></name><name name-style="western"><surname>Loirand</surname><given-names>G.</given-names></name><name name-style="western"><surname>Magnan</surname><given-names>A.</given-names></name></person-group><article-title>Prime role of IL-17A in neutrophilia and airway smooth muscle contraction in a house dust mite&#8211;induced allergic asthma model</article-title><source>J. Allergy Clin. Immunol.</source><year>2015</year><volume>135</volume><fpage>1643</fpage><lpage>1645.e5</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2014.12.1872</pub-id><pub-id pub-id-type="pmid">25649077</pub-id></element-citation></ref><ref id="B101-jcm-12-02294"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irvin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zafar</surname><given-names>I.</given-names></name><name name-style="western"><surname>Good</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rollins</surname><given-names>D.</given-names></name><name name-style="western"><surname>Christianson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gorska</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>R.</given-names></name></person-group><article-title>Increased frequency of dual-positive TH2/TH17 cells in bronchoalveolar lavage fluid characterizes a population of patients with severe asthma</article-title><source>J. Allergy Clin. Immunol.</source><year>2014</year><volume>134</volume><fpage>1175</fpage><lpage>1186.e7</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2014.05.038</pub-id><pub-id pub-id-type="pmid">25042748</pub-id><pub-id pub-id-type="pmcid">PMC4254017</pub-id></element-citation></ref><ref id="B102-jcm-12-02294"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Myou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fujimura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kamio</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kita</surname><given-names>T.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ishiura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakao</surname><given-names>S.</given-names></name></person-group><article-title>Effect of candesartan, a type 1 angiotensin II receptor antagonist, on bronchial hyper-responsiveness to methacholine in patients with bronchial asthma</article-title><source>Br. J. Clin. Pharmacol.</source><year>2002</year><volume>54</volume><fpage>622</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.2002.t01-4-01689.x</pub-id><pub-id pub-id-type="pmid">12492610</pub-id><pub-id pub-id-type="pmcid">PMC1874492</pub-id></element-citation></ref><ref id="B103-jcm-12-02294"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kankaanranta</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kauppi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tuomisto</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Ilmarinen</surname><given-names>P.</given-names></name></person-group><article-title>Emerging Comorbidities in Adult Asthma: Risks, Clinical Associations, and Mechanisms</article-title><source>Mediat. Inflamm.</source><year>2016</year><volume>2016</volume><fpage>3690628</fpage><pub-id pub-id-type="doi">10.1155/2016/3690628</pub-id><pub-id pub-id-type="pmcid">PMC4861800</pub-id><pub-id pub-id-type="pmid">27212806</pub-id></element-citation></ref><ref id="B104-jcm-12-02294"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enright</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Tracy</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Lasser</surname><given-names>E.C.</given-names></name></person-group><article-title>Asthma and Its Association with Cardiovascular Disease in the Elderly</article-title><source>J. Asthma</source><year>1996</year><volume>33</volume><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.3109/02770909609077762</pub-id><pub-id pub-id-type="pmid">8621370</pub-id></element-citation></ref><ref id="B105-jcm-12-02294"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Picado</surname><given-names>C.</given-names></name><name name-style="western"><surname>Deulofeu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Casals</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lleonart</surname><given-names>R.</given-names></name><name name-style="western"><surname>Agust&#237;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Quint&#243;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mullol</surname><given-names>J.</given-names></name></person-group><article-title>Lipid and protein metabolism in asthma. Effects of diet and corticosteroid therapy</article-title><source>Allergy</source><year>1999</year><volume>54</volume><fpage>569</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1034/j.1398-9995.1999.00024.x</pub-id><pub-id pub-id-type="pmid">10435470</pub-id></element-citation></ref><ref id="B106-jcm-12-02294"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J.</given-names></name></person-group><article-title>Association between lipid profile and the prevalence of asthma: A meta-analysis and systemic review</article-title><source>Curr. Med. Res. Opin.</source><year>2018</year><volume>34</volume><fpage>423</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1080/03007995.2017.1384371</pub-id><pub-id pub-id-type="pmid">28945108</pub-id></element-citation></ref><ref id="B107-jcm-12-02294"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Zelst</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>de Boer</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>T&#252;rk</surname><given-names>Y.</given-names></name><name name-style="western"><surname>van Huisstede</surname><given-names>A.</given-names></name><name name-style="western"><surname>Veen</surname><given-names>J.C.C.M.I.</given-names></name><name name-style="western"><surname>Birnie</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Klerk</surname><given-names>B.M.B.</given-names></name><name name-style="western"><surname>Stranders</surname><given-names>G.A.T.</given-names></name><name name-style="western"><surname>Braunstahl</surname><given-names>G.-J.</given-names></name></person-group><article-title>Association between elevated serum triglycerides and asthma in patients with obesity: An explorative study</article-title><source>Allergy Asthma Proc.</source><year>2021</year><volume>42</volume><fpage>e71</fpage><lpage>e76</lpage><pub-id pub-id-type="doi">10.2500/aap.2021.42.210020</pub-id><pub-id pub-id-type="pmid">33980342</pub-id></element-citation></ref><ref id="B108-jcm-12-02294"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alabed</surname><given-names>M.</given-names></name><name name-style="western"><surname>Elemam</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Ramakrishnan</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Sharif-Askari</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Kashour</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hamid</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Halwani</surname><given-names>R.</given-names></name></person-group><article-title>Therapeutic effect of statins on airway remodeling during asthma</article-title><source>Expert Rev. Respir. Med.</source><year>2022</year><volume>16</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1080/17476348.2021.1987890</pub-id><pub-id pub-id-type="pmid">34663161</pub-id></element-citation></ref><ref id="B109-jcm-12-02294"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serafino-Agrusa</surname><given-names>L.</given-names></name></person-group><article-title>Asthma and metabolic syndrome: Current knowledge and future perspectives</article-title><source>World J. Clin. Cases</source><year>2015</year><volume>3</volume><fpage>285</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.12998/wjcc.v3.i3.285</pub-id><pub-id pub-id-type="pmid">25789301</pub-id><pub-id pub-id-type="pmcid">PMC4360500</pub-id></element-citation></ref><ref id="B110-jcm-12-02294"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Wee</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>Y.I.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>K.-S.</given-names></name></person-group><article-title>Association Between Statin Medication and Asthma/Asthma Exacerbation in a National Health Screening Cohort</article-title><source>J. Allergy Clin. Immunol. Pract.</source><year>2021</year><volume>9</volume><fpage>2783</fpage><lpage>2791</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2021.04.014</pub-id><pub-id pub-id-type="pmid">33894391</pub-id></element-citation></ref><ref id="B111-jcm-12-02294"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>U.</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Forno</surname><given-names>E.</given-names></name></person-group><article-title>Obesity and asthma</article-title><source>J. Allergy Clin. Immunol.</source><year>2018</year><volume>141</volume><fpage>1169</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2018.02.004</pub-id><pub-id pub-id-type="pmid">29627041</pub-id><pub-id pub-id-type="pmcid">PMC5973542</pub-id></element-citation></ref><ref id="B112-jcm-12-02294"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dixon</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Poynter</surname><given-names>M.E.</given-names></name></person-group><article-title>Mechanisms of Asthma in Obesity. Pleiotropic Aspects of Obesity Produce Distinct Asthma Phenotypes</article-title><source>Am. J. Respir. Cell Mol. Biol.</source><year>2016</year><volume>54</volume><fpage>601</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2016-0017PS</pub-id><pub-id pub-id-type="pmid">26886277</pub-id><pub-id pub-id-type="pmcid">PMC4942199</pub-id></element-citation></ref><ref id="B113-jcm-12-02294"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miethe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karsonova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karaulov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Renz</surname><given-names>H.</given-names></name></person-group><article-title>Obesity and asthma</article-title><source>J. Allergy Clin. Immunol.</source><year>2020</year><volume>146</volume><fpage>685</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2020.08.011</pub-id><pub-id pub-id-type="pmid">33032723</pub-id></element-citation></ref><ref id="B114-jcm-12-02294"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bassi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name></person-group><article-title>Impact of Obesity on Response to Biologic Therapies in Patients with Inflammatory Bowel Diseases</article-title><source>Biodrugs</source><year>2022</year><volume>36</volume><fpage>197</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1007/s40259-022-00522-0</pub-id><pub-id pub-id-type="pmid">35320515</pub-id><pub-id pub-id-type="pmcid">PMC8994033</pub-id></element-citation></ref><ref id="B115-jcm-12-02294"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menzies-Gow</surname><given-names>A.</given-names></name><name name-style="western"><surname>Corren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bourdin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chupp</surname><given-names>G.</given-names></name><name name-style="western"><surname>Israel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wechsler</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Brightling</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Hellqvist</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>384</volume><fpage>1800</fpage><lpage>1809</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034975</pub-id><pub-id pub-id-type="pmid">33979488</pub-id></element-citation></ref><ref id="B116-jcm-12-02294"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>R.</given-names></name></person-group><article-title>Atherosclerosis as an inflammatory disease</article-title><source>N. Engl. J. Med.</source><year>1999</year><volume>340</volume><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1056/NEJM199901143400207</pub-id><pub-id pub-id-type="pmid">9887164</pub-id></element-citation></ref><ref id="B117-jcm-12-02294"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansson</surname><given-names>G.K.</given-names></name></person-group><article-title>Inflammation, Atherosclerosis, and Coronary Artery Disease</article-title><source>N. Engl. J. Med.</source><year>2005</year><volume>352</volume><fpage>1685</fpage><lpage>1695</lpage><pub-id pub-id-type="doi">10.1056/NEJMra043430</pub-id><pub-id pub-id-type="pmid">15843671</pub-id></element-citation></ref><ref id="B118-jcm-12-02294"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Croce</surname><given-names>K.</given-names></name><name name-style="western"><surname>Libby</surname><given-names>P.</given-names></name></person-group><article-title>Inflammation in Atherosclerosis</article-title><source>Arter. Thromb. Vasc. Biol.</source><year>2012</year><volume>32</volume><fpage>2045</fpage><lpage>2051</lpage><pub-id pub-id-type="doi">10.1161/atvbaha.108.179705</pub-id><pub-id pub-id-type="pmcid">PMC3422754</pub-id><pub-id pub-id-type="pmid">22895665</pub-id></element-citation></ref><ref id="B119-jcm-12-02294"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ridker</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Everett</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Thuren</surname><given-names>T.</given-names></name><name name-style="western"><surname>MacFadyen</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Ballantyne</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nicolau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Koenig</surname><given-names>W.</given-names></name><name name-style="western"><surname>Anker</surname><given-names>S.D.</given-names></name><etal/></person-group><article-title>Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>377</volume><fpage>1119</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1707914</pub-id><pub-id pub-id-type="pmid">28845751</pub-id></element-citation></ref><ref id="B120-jcm-12-02294"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>G.-P.</given-names></name><name name-style="western"><surname>Bot</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kovanen</surname><given-names>P.T.</given-names></name></person-group><article-title>Mast cells in human and experimental cardiometabolic diseases</article-title><source>Nat. Rev. Cardiol.</source><year>2015</year><volume>12</volume><fpage>643</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1038/nrcardio.2015.117</pub-id><pub-id pub-id-type="pmid">26259935</pub-id></element-citation></ref><ref id="B121-jcm-12-02294"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niccoli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Montone</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Sabato</surname><given-names>V.</given-names></name><name name-style="western"><surname>Crea</surname><given-names>F.</given-names></name></person-group><article-title>Role of Allergic Inflammatory Cells in Coronary Artery Disease</article-title><source>Circulation</source><year>2018</year><volume>138</volume><fpage>1736</fpage><lpage>1748</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.035400</pub-id><pub-id pub-id-type="pmid">30354461</pub-id></element-citation></ref><ref id="B122-jcm-12-02294"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sukhova</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Wolters</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kitamoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Libby</surname><given-names>P.</given-names></name><name name-style="western"><surname>A Macfarlane</surname><given-names>L.</given-names></name><name name-style="western"><surname>Clair</surname><given-names>J.M.-S.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>G.-P.</given-names></name></person-group><article-title>Mast cells promote atherosclerosis by releasing proinflammatory cytokines</article-title><source>Nat. Med.</source><year>2007</year><volume>13</volume><fpage>719</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1038/nm1601</pub-id><pub-id pub-id-type="pmid">17546038</pub-id></element-citation></ref><ref id="B123-jcm-12-02294"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sukhova</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wolters</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>MacFarlane</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Libby</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ennis</surname><given-names>T.L.</given-names></name><etal/></person-group><article-title>Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice</article-title><source>J. Clin. Investig.</source><year>2007</year><volume>117</volume><fpage>3359</fpage><lpage>3368</lpage><pub-id pub-id-type="doi">10.1172/JCI31311</pub-id><pub-id pub-id-type="pmid">17932568</pub-id><pub-id pub-id-type="pmcid">PMC2000808</pub-id></element-citation></ref><ref id="B124-jcm-12-02294"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sj&#246;berg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tia</surname><given-names>V.</given-names></name><name name-style="western"><surname>Secco</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sukhova</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>G.-P.</given-names></name></person-group><article-title>Pharmaceutical stabilization of mast cells attenuates experimental atherogenesis in low-density lipoprotein receptor-deficient mice</article-title><source>Atherosclerosis</source><year>2013</year><volume>229</volume><fpage>304</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2013.05.025</pub-id><pub-id pub-id-type="pmid">23880180</pub-id><pub-id pub-id-type="pmcid">PMC3724238</pub-id></element-citation></ref><ref id="B125-jcm-12-02294"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furukawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kuwabara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lawton</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>T.</given-names></name></person-group><article-title>Mast Cell Promotes the Development of Intracranial Aneurysm Rupture</article-title><source>Stroke</source><year>2020</year><volume>51</volume><fpage>3332</fpage><lpage>3339</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.120.030834</pub-id><pub-id pub-id-type="pmid">33019897</pub-id><pub-id pub-id-type="pmcid">PMC7606717</pub-id></element-citation></ref><ref id="B126-jcm-12-02294"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marx</surname><given-names>C.</given-names></name><name name-style="western"><surname>Novotny</surname><given-names>J.</given-names></name><name name-style="western"><surname>Salbeck</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zellner</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Nicolai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pekayvaz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kilani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stockhausen</surname><given-names>S.</given-names></name><name name-style="western"><surname>B&#252;rgener</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kupka</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps</article-title><source>Blood</source><year>2019</year><volume>134</volume><fpage>1859</fpage><lpage>1872</lpage><pub-id pub-id-type="doi">10.1182/blood.2019000518</pub-id><pub-id pub-id-type="pmid">31481482</pub-id><pub-id pub-id-type="pmcid">PMC6908806</pub-id></element-citation></ref><ref id="B127-jcm-12-02294"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gudbjartsson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bjornsdottir</surname><given-names>U.S.</given-names></name><name name-style="western"><surname>Halapi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Helgadottir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sulem</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jonsdottir</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Thorleifsson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Helgadottir</surname><given-names>H.</given-names></name><name name-style="western"><surname>Steinthorsdottir</surname><given-names>V.</given-names></name><name name-style="western"><surname>Stefansson</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction</article-title><source>Nat. Genet.</source><year>2009</year><volume>41</volume><fpage>342</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1038/ng.323</pub-id><pub-id pub-id-type="pmid">19198610</pub-id></element-citation></ref><ref id="B128-jcm-12-02294"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madjid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Awan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Willerson</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Casscells</surname><given-names>S.W.</given-names></name></person-group><article-title>Leukocyte count and coronary heart disease: Implications for risk assessment</article-title><source>J. Am. Coll. Cardiol.</source><year>2004</year><volume>44</volume><fpage>1945</fpage><lpage>1956</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2004.07.056</pub-id><pub-id pub-id-type="pmid">15542275</pub-id></element-citation></ref><ref id="B129-jcm-12-02294"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madjid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fatemi</surname><given-names>O.</given-names></name></person-group><article-title>Components of the complete blood count as risk predictors for coronary heart disease: In-depth review and update</article-title><source>Tex. Hear. Inst. J.</source><year>2013</year><volume>40</volume><fpage>17</fpage><lpage>29</lpage><pub-id pub-id-type="pmcid">PMC3568280</pub-id><pub-id pub-id-type="pmid">23467296</pub-id></element-citation></ref><ref id="B130-jcm-12-02294"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pongdee</surname><given-names>T.</given-names></name><name name-style="western"><surname>Manemann</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Decker</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Larson</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Killian</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kita</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bielinski</surname><given-names>S.J.</given-names></name></person-group><article-title>Rethinking blood eosinophil counts: Epidemiology, associated chronic diseases, and increased risks of cardiovascular disease</article-title><source>J. Allergy Clin. Immunol. Glob.</source><year>2022</year><volume>1</volume><fpage>233</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/j.jacig.2022.09.001</pub-id><pub-id pub-id-type="pmid">36466741</pub-id><pub-id pub-id-type="pmcid">PMC9718542</pub-id></element-citation></ref><ref id="B131-jcm-12-02294"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niccoli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Calvieri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Flego</surname><given-names>D.</given-names></name><name name-style="western"><surname>Scalone</surname><given-names>G.</given-names></name><name name-style="western"><surname>Imaeva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sabato</surname><given-names>V.</given-names></name><name name-style="western"><surname>Schiavino</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liuzzo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Crea</surname><given-names>F.</given-names></name></person-group><article-title>Allergic Inflammation Is Associated with Coronary Instability and a Worse Clinical Outcome After Acute Myocardial Infarction</article-title><source>Circ. Cardiovasc. Interv.</source><year>2015</year><volume>8</volume><fpage>e002554</fpage><pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.115.002554</pub-id><pub-id pub-id-type="pmid">26243785</pub-id></element-citation></ref><ref id="B132-jcm-12-02294"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pizzolo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Castagna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Olivieri</surname><given-names>O.</given-names></name><name name-style="western"><surname>Girelli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Friso</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stefanoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Udali</surname><given-names>S.</given-names></name><name name-style="western"><surname>Munerotto</surname><given-names>V.</given-names></name><name name-style="western"><surname>Baroni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cetera</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Basophil Blood Cell Count Is Associated with Enhanced Factor II Plasma Coagulant Activity and Increased Risk of Mortality in Patients with Stable Coronary Artery Disease: Not Only Neutrophils as Prognostic Marker in Ischemic Heart Disease</article-title><source>J. Am. Hear. Assoc.</source><year>2021</year><volume>10</volume><fpage>e018243</fpage><pub-id pub-id-type="doi">10.1161/JAHA.120.018243</pub-id><pub-id pub-id-type="pmcid">PMC8174269</pub-id><pub-id pub-id-type="pmid">33624506</pub-id></element-citation></ref><ref id="B133-jcm-12-02294"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morshed</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hlushchuk</surname><given-names>R.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Obata-Ninomiya</surname><given-names>K.</given-names></name><name name-style="western"><surname>Karasuyama</surname><given-names>H.</given-names></name><name name-style="western"><surname>Djonov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Eggel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>H.-U.</given-names></name><etal/></person-group><article-title>NADPH Oxidase&#8211;Independent Formation of Extracellular DNA Traps by Basophils</article-title><source>J. Immunol.</source><year>2014</year><volume>192</volume><fpage>5314</fpage><lpage>5323</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1303418</pub-id><pub-id pub-id-type="pmid">24771850</pub-id></element-citation></ref><ref id="B134-jcm-12-02294"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno-Sanchez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hernandez-Ruiz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Docampo</surname><given-names>R.</given-names></name></person-group><article-title>Polyphosphate Is a Novel Pro-inflammatory Regulator of Mast Cells and Is Located in Acidocalcisomes</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>28435</fpage><lpage>28444</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.385823</pub-id><pub-id pub-id-type="pmid">22761438</pub-id><pub-id pub-id-type="pmcid">PMC3436523</pub-id></element-citation></ref><ref id="B135-jcm-12-02294"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Morrissey</surname><given-names>J.H.</given-names></name></person-group><article-title>Polyphosphate: A new player in the field of hemostasis</article-title><source>Curr. Opin. Hematol.</source><year>2014</year><volume>21</volume><fpage>388</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1097/MOH.0000000000000069</pub-id><pub-id pub-id-type="pmid">25010799</pub-id><pub-id pub-id-type="pmcid">PMC4415375</pub-id></element-citation></ref><ref id="B136-jcm-12-02294"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Onufrak</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abramson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vaccarino</surname><given-names>V.</given-names></name></person-group><article-title>Adult-onset asthma is associated with increased carotid atherosclerosis among women in the atherosclerosis risk in communities (ARIC) study</article-title><source>Atherosclerosis</source><year>2007</year><volume>195</volume><fpage>129</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2006.09.004</pub-id><pub-id pub-id-type="pmid">17045272</pub-id><pub-id pub-id-type="pmcid">PMC2128256</pub-id></element-citation></ref><ref id="B137-jcm-12-02294"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pacholczak-Madej</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kuszmiersz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Iwaniec</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zar&#281;ba</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zarychta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Walocha</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dropi&#324;ski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bazan-Socha</surname><given-names>S.</given-names></name></person-group><article-title>Endothelial Dysfunction and Pentraxin-3 in Clinically Stable Adult Asthma Patients</article-title><source>J. Investig. Allergol. Clin. Immunol.</source><year>2021</year><volume>31</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.18176/jiaci.0563</pub-id><pub-id pub-id-type="pmid">32376513</pub-id></element-citation></ref><ref id="B138-jcm-12-02294"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bazan-Socha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mastalerz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cybulska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zareba</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kremers</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zabczyk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pulka</surname><given-names>G.</given-names></name><name name-style="western"><surname>Iwaniec</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hemker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Undas</surname><given-names>A.</given-names></name></person-group><article-title>Asthma is associated with enhanced thrombin formation and impaired fibrinolysis</article-title><source>Clin. Exp. Allergy</source><year>2016</year><volume>46</volume><fpage>932</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1111/cea.12734</pub-id><pub-id pub-id-type="pmid">27019085</pub-id></element-citation></ref><ref id="B139-jcm-12-02294"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhee</surname><given-names>T.-M.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>E.-K.</given-names></name><name name-style="western"><surname>Han</surname><given-names>K.-D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.-R.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>S.</given-names></name></person-group><article-title>Impact of the Combinations of Allergic Diseases on Myocardial Infarction and Mortality</article-title><source>J. Allergy Clin. Immunol. Pract.</source><year>2021</year><volume>9</volume><fpage>872</fpage><lpage>880.e4</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2020.09.008</pub-id><pub-id pub-id-type="pmid">32961311</pub-id></element-citation></ref><ref id="B140-jcm-12-02294"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tattersall</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Korcarz</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Gepner</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Barr</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>McClelland</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Delaney</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Asthma Predicts Cardiovascular Disease Events: The multi-ethnic study of atherosclerosis</article-title><source>Arter. Thromb. Vasc. Biol.</source><year>2015</year><volume>35</volume><fpage>1520</fpage><lpage>1525</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.115.305452</pub-id><pub-id pub-id-type="pmcid">PMC4441553</pub-id><pub-id pub-id-type="pmid">25908767</pub-id></element-citation></ref><ref id="B141-jcm-12-02294"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strand</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S.-S.</given-names></name><name name-style="western"><surname>Brumpton</surname><given-names>B.M.</given-names></name></person-group><article-title>Is having asthma associated with an increased risk of dying from cardiovascular disease? A prospective cohort study of 446 346 Taiwanese adults</article-title><source>BMJ Open</source><year>2018</year><volume>8</volume><fpage>e019992</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2017-019992</pub-id><pub-id pub-id-type="pmcid">PMC5988076</pub-id><pub-id pub-id-type="pmid">29858410</pub-id></element-citation></ref><ref id="B142-jcm-12-02294"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Min</surname><given-names>C.</given-names></name><name name-style="western"><surname>Byun</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>B.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H.G.</given-names></name></person-group><article-title>Association between asthma and cardiovascular disease</article-title><source>Eur. J. Clin. Investig.</source><year>2021</year><volume>51</volume><fpage>e13396</fpage><pub-id pub-id-type="doi">10.1111/eci.13396</pub-id><pub-id pub-id-type="pmid">32888313</pub-id></element-citation></ref><ref id="B143-jcm-12-02294"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.-F.</given-names></name><name name-style="western"><surname>An</surname><given-names>Z.-Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>M.-D.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Song</surname><given-names>A.-J.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Association Between Asthma and All-Cause Mortality and Cardiovascular Disease Morbidity and Mortality: A Meta-Analysis of Cohort Studies</article-title><source>Front. Cardiovasc. Med.</source><year>2022</year><volume>9</volume><fpage>861798</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2022.861798</pub-id><pub-id pub-id-type="pmid">35369308</pub-id><pub-id pub-id-type="pmcid">PMC8968068</pub-id></element-citation></ref><ref id="B144-jcm-12-02294"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>Allergic asthma aggravated atherosclerosis increases cholesterol biosynthesis and foam cell formation in apolipoprotein E-deficient mice</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2019</year><volume>519</volume><fpage>861</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2019.09.085</pub-id><pub-id pub-id-type="pmid">31558320</pub-id></element-citation></ref><ref id="B145-jcm-12-02294"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunstone</surname><given-names>R.F.</given-names></name></person-group><article-title>Right heart pressures in bronchial asthma</article-title><source>Thorax</source><year>1971</year><volume>26</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1136/thx.26.1.39</pub-id><pub-id pub-id-type="pmid">5101268</pub-id><pub-id pub-id-type="pmcid">PMC472232</pub-id></element-citation></ref><ref id="B146-jcm-12-02294"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karasu</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Ayd&#305;ncak</surname><given-names>H.T.</given-names></name></person-group><article-title>Right ventricular-pulmonary arterial uncoupling in mild-to-moderate asthma</article-title><source>J. Asthma</source><year>2022</year><volume>12</volume><fpage>543</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1080/02770903.2022.2073548</pub-id><pub-id pub-id-type="pmid">35502969</pub-id></element-citation></ref><ref id="B147-jcm-12-02294"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harkness</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Kanabar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Westergren-Thorsson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Larsson-Callerfelt</surname><given-names>A.-K.</given-names></name></person-group><article-title>Pulmonary vascular changes in asthma and COPD</article-title><source>Pulm. Pharmacol. Ther.</source><year>2014</year><volume>29</volume><fpage>144</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.pupt.2014.09.003</pub-id><pub-id pub-id-type="pmid">25316209</pub-id></element-citation></ref><ref id="B148-jcm-12-02294"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shedeed</surname><given-names>S.A.</given-names></name></person-group><article-title>Right Ventricular Function in Children with Bronchial Asthma: A Tissue Doppler Echocardiographic Study</article-title><source>Pediatr. Cardiol.</source><year>2010</year><volume>31</volume><fpage>1008</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1007/s00246-010-9753-2</pub-id><pub-id pub-id-type="pmid">20697704</pub-id></element-citation></ref><ref id="B149-jcm-12-02294"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozde</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dogru</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ozde</surname><given-names>&#350;.</given-names></name><name name-style="western"><surname>Kayapinar</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kaya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Korkmaz</surname><given-names>A.</given-names></name></person-group><article-title>Subclinical right ventricular dysfunction in intermittent and persistent mildly asthmatic children on tissue Doppler echocardiography and serum NT -pro BNP: Observational study</article-title><source>Pediatr. Int.</source><year>2018</year><volume>60</volume><fpage>1024</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1111/ped.13689</pub-id><pub-id pub-id-type="pmid">30179288</pub-id></element-citation></ref><ref id="B150-jcm-12-02294"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suissa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Assimes</surname><given-names>T.</given-names></name><name name-style="western"><surname>Brassard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ernst</surname><given-names>P.</given-names></name></person-group><article-title>Inhaled corticosteroid use in asthma and the prevention of myocardial infarction</article-title><source>Am. J. Med.</source><year>2003</year><volume>115</volume><fpage>377</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1016/S0002-9343(03)00393-0</pub-id><pub-id pub-id-type="pmid">14553873</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="jcm-12-02294-f001" orientation="portrait"><label>Figure 1</label><caption><p>Overview of different conditions potentially coexisting and interacting with bronchial asthma. Grey, thick arrows indicate a pathobiological contribution in the development of the disease; green, thin arrows highlight a negative impact on the disease control, burden and evolution. AATD: &#945;1-Antitrypsin deficiency; ABPA: allergic bronchopulmonary aspergillosis; EGPA: eosinophilic granulomatosis with polyangiitis; CEP: Chronic Eosinophilic Pneumonia; CVD: cardiovascular Disease; HES: Hyper-eosinophilic Syndrome; SCD: Sickle Cell Disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jcm-12-02294-g001.jpg"/></fig></floats-group></article></pmc-articleset>